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ABSTRACT
Lysine acetylation is a prevalent post-translational modification whose
multi-varied biological roles have recently emerged. While having all the
necessary components of a signaling network, lysine acetylation studies have
been limited to a small subset of proteins and pathways. Using a quantitative
unbiased mass spectrometry approach, we explored the role of growth factor
stimulation on lysine acetylation. Although the growth factors bind receptor
tyrosine kinases, growth factor stimulation resulted in rapid and dynamic changes
in lysine acetylation. Furthermore, we demonstrated that short-term HDAC
inhibition alters phosphotyrosine-signaling networks. To better understand this
behavior, a suite of biochemical and computational methods were
developed. Bromodomains were engineered to explore binding preferences
using degenerate peptide arrays as well as develop acetyllysine affinity reagents
as an alternative to anti-acetyllysine antibodies. Additionally, bioorthogonal
proteomics were employed to identify acetyltransferase substrates. Taken
together, the knowledge generated and the methods developed provide a toolkit
for the analysis of lysine acetylation networks in the context of many biological
processes as well as diseases.
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Title: Associate Professor of Biological Engineering
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Chapter 1 : Introduction
Biochemical Signaling
Biochemical signaling underlies a diverse array of cellular behaviors in
mammalian cells. Broadly, these biochemical signals function to control
metabolism, growth, differentiation, protein synthesis, movement and a wide
array of other cellular processes. Generally speaking, signals can have
intracellular or extracellular origins and can act over a variety of length and
timescales. Signaling molecules, or ligands, encompass a wide diversity of
molecules: lipid derivatives, peptides, and proteins. Of particular interest to this
thesis are protein ligands, namely growth factors. These ligands then bind to a
complementary site on a receptor. This binding often induces a conformational
change in the receptor. These conformational changes enables the interaction of
these proteins with other intracellular proteins; these interactions can induce a
signaling cascade that can propagate into a pathway or signaling network,
thereby allowing the cell to convert these cues into phenotypic responses such
as those described above.
Intracellular signaling relies on a number of different protein components in
order to propagate the input signal. Classical signaling literature considers
enzymes such as GTPases, kinases, phosphatases and other proteins such as
transcription factors to be critical regulatory components of intracellular signaling.
These proteins interact with one another through complex interactions that give
rise to a diverse array of biologic responses. Of particular interest to this thesis
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are the protein kinases of which there are over 500 encoded in the human
genome (Manning et al., 2002). Mammalian protein kinases are enzymes that
chemically modify proteins by the addition of a phosphate to a substrate protein.
These mammalian protein kinases transfer phosphate groups onto the hydroxyl
groups of serine, threonine, and tyrosine. Phosphorylation of these proteins can
result in a conformational change of these proteins, a change in localization,
altered association with other proteins, or a change in activity. Kinases can be
further classified based on their localization: intracellular kinases and receptor
tyrosine kinases, which are largely membrane bound. While phosphorylation
plays a critical role in mediating cellular responses, the dynamics and regulation
of this modification are critical to achieving a finely tuned response to a variety of
stimuli. In order to maintain this delicate balance, cells make use of a broad
class of proteins in order to regulate amino acid phosphorylation. These proteins
involve the "writer" and "reader" proteins, kinases and phosphatases,
respectively, that add and remove the modification, as well as the "reader,"
phospho-binding protein domains that recognize the modification and thereby
enable a diverse range of protein-protein interactions (Figure 1.1).
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Phosphatases
pY
Protein
Figure 1-1: The components of phosphotyrosine signaling machinery. Kinases
add the modification, phosphatases remove the modification, and SH2/PTB
domains recognize the modification.
In order to drive this diverse range of responses, cells make use of a range of
signaling cascades that allow the cells to transmit signals from a wide variety of
stimuli. These signaling cascades are often considered in the context of a
pathway or cascade where the activation of one protein leads to the activation of
another. One pathway of note is the mitogen-activated protein kinase pathway.
This pathway can be activated when a phosphorylated receptor tyrosine kinase
binds the GRB2 scaffold protein, which further engages the Sos adaptor protein
and the Ras GTPase. After association with Sos, Ras switches from a GDP-
bound state to a GTP-bound, active conformation. Activated Ras binds and
activates Raf, leading to subsequent phosphorylation and activation of MEK, a
dual-specificity protein-kinase that phosphorylates the ERK1 and ERK2 mitogen
activated protein kinases (MAPK) which then can go on to phosphorylate a wide
variety of proteins (Figure 1-2).
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Figure 1-2: MAP Kinase Pathway. This pathway is activated by a sequence of protein
binding events and activation of a variety of enzymes. Though shown in a simple
representation, other proteins and feedback loops are known to influence this pathway as
well.
While many studies have focused exclusively on the MAPK pathway and its
organization, recent research has focused on integrating multiple biological
pathways into complex networks involving a diverse array of protein-protein
interactions and enzymatic reactions. One such example is the epidermal growth
factor receptor (EGFR) signaling network (Figure 1-3).
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EGFR
MEK1/2
BADp7
Figure 1-3: EGFR signaling network. Activation of EGFR leads to the activation of a
variety of enzymes, pathways. Furthermore, phosphorylation of the receptor provides a
wide array of docking sites for protein-protein interactions.
In concert with the paradigm shift from pathways to networks, approaches to
analyze understand how these networks are regulated have emerged. These
approaches include transcriptional profiling, mass spectrometry, and flow
cytometry as well as a number of different computational techniques to integrate
these data into a network model. Together, these approaches provide a
comprehensive understanding of how cells integrate a variety of signals both
intracellular and extracellular in origin.
Receptor Tyrosine Kinase Signaling
Of particular interest to this work are three receptor tyrosine kinases,
epidermal growth factor receptor, insulin-like growth factor receptor (IGFR), and
insulin receptor (IR). These receptor tyrosine kinases have been implicated in
regulating a variety of biological responses ranging from metastasis to glucose
regulation.
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EGFR belongs a family of transmembrane receptor tyrosine kinases, the
ERBB or EGFR family of proteins. Since the early discovery of the ligand in the
1960s and the receptor in the 1970s, research on EGFR has identified the
remaining members of this protein family, the many ligands of this protein, as
well as identifying a role for the enzyme in cancer (Carpenter et al., 1975; Cohen,
1965).
The EGFR family of proteins consists of four members (ERBB1/EGFR,
ERBB2/HER2, ERBB3/HER3, and ERBB4/HER) and can bind many ligands.
These receptors share similar structural elements consisting of an extracellular
domain, a hydrophobic transmembrane domain, and a cytoplasmic domain.
Diversity in these proteins is borne out of the extracellular and cytoplasmic
domains. For example, while EGFR, HER3, and HER4 can bind extracellular
ligands, HER2 cannot. Similarly, the cytoplasmic domains of EGFR and HER4
have been shown to have kinase activity while HER2 and HER3 do not. One
additional layer of diversity in the EGFR family of proteins is driven by the
dimerization status of these proteins. The extracellular domains of these proteins
are capable of homo- or heterodimerizing with one another allowing for a diverse
array of dimers that can lead to an extensive range of responses.
In order to drive this wide array of responses, upon ligand binding to
EGFR, autophosphorylation of the receptor creates a variety of docking sites for
a wide variety of other proteins. These docking sites act as the initiation site of a
wide variety of signaling pathways such as the MAP kinase pathway described
earlier as well as the phosphoinositide-3-kinase (P13K) pathway, signal
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transduction and activator of transcription (STAT) pathway, and others. The
effects of EGFR activation are not limited to activation of these pathways. As
described above, these pathways assemble into a complex interconnected
network of protein-protein interactions that drive cell migration, differentiation,
and proliferation.
Insulin-like growth factor receptor (IGFR) is another receptor tyrosine
kinase. Similar to EGFR, it contains extracellular, transmembrane, and
intracellular domains. Synthesized from a single mRNA precursor, the resulting
protein is glycosylated, folded, and then dimerized. It is subsequently cleaved
into its component alpha and beta chains. A disulfide linkage then connects the
two domains. The alpha chain exists extracellularly, while the beta chain spans
the cell membrane and also has a cytoplasmic domain with a tyrosine kinase
domain. The receptor shares 70% amino acid homology with the insulin
receptor, and has been shown to form heterodimers with the insulin receptor.
This homology has made therapeutic targeting of IGFR difficult.
Ligand binding of IGFR leads to phosphorylation of the cytoplasmic
domain of the receptor. Phosphorylation of these residues leads to the
recruitment and docking of scaffolding proteins such as Src homology 2 domain
containing transforming protein 1 (Shc), 14-3-3, and insulin receptor substrate
protein 1 (IRS1) (Craparo et al., 1995, 1997; De Meyts et al., 1994). These
scaffolding proteins act as functional links to connect ligand binding at the
receptor to further downstream signaling networks. For example, Shc is
recruited to phosphorylated tyrosine residue (Tyr950) in the juxtamembrane
17
region of the IGF1 R, and drives the activation of the MAP kinase pathway.
Following phosphorylation of IRS-1 by IGFR, the P13K pathway is activated when
the regulatory subunit of P13K binds to phosphorylated IRS-1. Activation of P13K
leads to the subsequent membrane localization and activation of the kinase AKT.
Signaling downstream of IGFR has been implicated in normal mammalian
development, as well as muscle hypertrophy and cancer.
The insulin receptor (IR) is also a receptor tyrosine kinase. Structurally, it
is very similar to IGFR. Synthesized from a single mRNA, the receptor is
composed of an alpha and beta subunit. These subunits are linked via a
disulfide linkage. These monomers then dimerize with another insulin receptor
monomer to form the complete receptor. Insulin receptor is capable of binding
insulin as well as insulin-like growth factors 1 and 2.
Upon ligand binding, the insulin receptor undergoes a conformational
change thereby allowing for the autophosphorylation of many tyrosine residues in
the protein's kinase domain. Similar to the other receptor tyrosine kinases
described, these phosphorylated residues provide docking sites for many other
scaffolding proteins that assist in propagating the ligand-binding signal across the
network. Physiologically, insulin signaling has been demonstrated to have a role
in regulating glucose homeostasis. For example, insulin signaling has been
demonstrated to alter the localization of the glucose transporter, Glut4, to the cell
membrane of adipocytes and muscle cells leading to uptake of glucose from the
blood stream (Kanai et al., 1993). Dysregulation of this signaling network has
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been implicated in the development of type 2 diabetes and other metabolic
disorders.
While phosphorylation has often been implicated as the major regulator of
cellular signaling networks, cells make use of a wide variety of other post-
translational modifications, including lysine methylation, lysine acetylation, and
others, to regulate cellular responses. Post-translational modifications can occur
on a vast array of amino acids, and their presence is induced by a wide array of
stimuli and regulated by a large number of enzymes. The fact that proteins can
be modified by multiple post-translational modifications at the same time creates
a very complex array of protein states and potentially a diverse array of protein
activities. For example, phosphorylation of Tyr1045 of EGF recruits the E3
ubiquitin-ligase Cbl, which tags the protein with ubiquitin for subsequent
internalization and degradation (Levkowitz et al., 1998). The interaction between
tyrosine phosphorylation and ubiquitination of EGFR is just one example of the
complex interconnectivity of protein modifications.
Lysine Acetylation
Lysine acetylation is a prevalent post-translational modification whose
multi-varied biological roles are just emerging. Historically, lysine acetylation has
been studied in the context of transcriptional regulation. For years, much of the
focus of acetylation has focused on histones, and many of the enzymes known to
regulate acetylation have been named to reflect the relationship with histones.
For example, histone deacetylases (HDACs) and lysine deacetylases (KDACs)
are one and the same. Acetylation of histones removes the positive charge on
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the lysine, thereby decreasing the interaction of the histones with negatively
charged DNA. As a result, the chromatin that was previously wrapped around
the histones takes on a more relaxed structure, and in some cases, this altered
chromatin structure is associated with increased transcription. Recent studies
have implicated lysine acetylation in regulating a wide variety of biological
responses. For example, the lysine deacetylase, SirT1, has been shown to
influence glucose uptake in adipocytes (Yoshizaki et al., 2009). Classically,
phosphorylation events downstream of insulin receptor were thought to drive
increased glucose uptake. Yoshizaki and colleagues knocked down SirT1 in
adipocytes and demonstrated altered glucose uptake in response to insulin
treatment. This study, and others now demonstrates a potential role for lysine
acetylation in regulating this phenotype. Despite the observation that knockdown
of SirT1 influences glucose uptake, explaining this altered response remains
challenging. More work is necessary to understand and explain how lysine
acetylation and tyrosine phosphorylation networks work in concert with one
another to elicit a particular phenotype.
Similar to tyrosine phosphorylation, lysine acetylation is controlled by the
regulated activities of enzymes that add and remove the modification (Figure 1-
20
5).
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Figure 1-4: The components of acetyllysine signaling machinery. Acetyltransferases add the
modification, deacetylases remove the modification, and bromodomains recognize the
modification.
The enzymes that add the modification, the acetyltransferases, use acetyl-
CoA to coordinate the transfer of the acetyl group from acetyl-CoA to the epsilon
amine of a lysine residue on the protein substrate. There are many lysine
acetyltransferases, and broadly, they can be grouped into three families, the
GNAT family, the MYST family, and the p300/CBP family. Delineation amongst
these families is largely driven by the domain composition of the various
acetyltransferases (Roth et al., 2001).
Histone deacetylases remove the acetyl group from protein substrates.
The deacetylases can be broadly subdivided into two categories depending on
the cofactor used in their deacetylation reactions. The two categories of
deacetylases are the classical HDACs, and the sirtuins. Within each category
exists a broad swath of member enzymes. In mammals, there are 11 Zn-
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dependent deacetylases, and 7 NAD-dependent deacetylases. It is important to
note that not all of these enzymes have been demonstrated to have deacetylase
activity, but have rather been categorized as HDACs due to their sequence
homology compared to functionally-characterized deacetylases.
Lastly, similar to phosphotyrosine-binding domains, bromodomains are
protein domains that are capable of recognizing and binding to acetylated
residues. Bromodomains are comprised of four alpha helices that adopt an all-
alpha protein fold and have been shown to bind to a wide variety of histones and
histone peptides; however, their broad binding range across the proteome has
not been explored. Furthermore, it has been shown that the bromodomains
display a substrate preference across the histone proteome suggesting that
responses may be tuned by the specificity of this interaction. While studies have
largely focused on the histone proteins and their interaction with bromodomains,
it is entirely conceivable that bromodomains may have non-nuclear binding
partners since some of these bromodomains exist outside of the nucleus as well.
Signaling in Cancer
While signaling is responsible for regulating activities very critical in
growth, metabolism, and other cellular responses, dysregulation of cellular
signaling has been implicated in cancer. Cancer progression is characterized by
the acquisition of a number of alterations in the capacity to invade, metastasize,
evade apoptosis, and proliferate in the absence of growth stimuli. Underlying
these altered phenotypic responses are altered signaling pathways that drive
these changes. For example, molecular characterization efforts have identified
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the amplification, over-expression, and mutation of EGFR in glioblastoma
multiforme and many other tumor types (Gan et al., 2009; Heimberger et al.,
2005). One example of mutations of receptors in cancer is the mutation of
leucine 858 on EGFR to arginine (L858R) (Mitsudomi and Yatabe, 2010; Rosell
et al., 2009). This mutation in the kinase domain of the receptor confers
increased sensitivity to tyrosine kinase inhibitors (Rosell et al., 2012). One
example of EGFR mutation is EGFR variant Ill, which is most commonly
expressed in human tumors. This mutant lacks a major portion of the ligand-
binding domain, and is constitutively active. Another example of aberrant
signaling driving tumorigenesis is the small GTPase, Ras. Mutations in the Ras
family of proteins are found in 20%-30% of all tumors (Bos, 1989; Downward,
2003). The enzyme is rendered constitutively active by a mutation of glycine
(Gly12) to a number of other residues. This renders the GTPase domain of Ras
insensitive to inactivation allowing the enzyme to subsequently activate many
downstream pathways, which may lead to uncontrolled growth and proliferation.
These examples demonstrate the important role for signaling in cancer and also
demonstrate how aberrant signaling can contribute to tumor etiology.
Cancer Therapeutics: Targeting the Signaling Network
The observation that dysregulated signaling is a major contributor in
cancer etiology has resulted in a concerted effort to attempt to target signaling
pathways in cancer (Downward, 2003; Engelman, 2009; Huang and Houghton,
2003; Kohno and Pouyssegur, 2006). Various nodes throughout the network
have been identified as potential targets, including receptor tyrosine kinases,
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mutant non-receptor tyrosine kinases, and critical points of confluency within the
network. Multiple therapeutics have been developed against receptor tyrosine
kinases, with many of these compounds targeting EGFR (Herbst et al., 2004;
Mendelsohn and Baselga, 2000, 2006; Scaltriti and Baselga, 2006). Small
molecule kinase inhibitors have been approved for the treatment of cancers
where EGFR has been shown to be hyperactive. These small molecule drugs
function as ATP analogs that block the access of ATP to the catalytic domain of
the tyrosine kinases. Two such drugs have been clinically approved for the
treatment of non-small cell lung cancer, gefitinib and erlotinib (Amann et al.,
2005). Other approaches to target EGFR include the use of monoclonal
antibodies, developed to interfere with the ligand binding of the receptor or the
dimerization of the receptor. Other intervention efforts have focused on
interfering with non-receptor tyrosine kinases. For example, in chronic
myelogenous leukemia (CML), a fusion of the protein tyrosine kinase AbI and the
breakpoint cluster region protein (Bcr) results in a constitutively active mutant
form of the kinase that has been demonstrated to play a critical role in the growth
of the survival of the leukemia (Lugo et al., 1990). Inhibitors were designed to
target this kinase, and in 2001, imatinib (Gleevec) was approved after it was
shown to have dramatically positive effects in patients with CML (Druker et al.,
2001). Despite these successes, targeting of signaling pathways remains a
challenging task. Cancers often become resistance to these inhibitors, and
oftentimes these cancers can recur. Combination therapies have been explored
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as a way to circumvent the challenges presented by monotherapy approaches
and continue to be an active research area.
In addition to targeting kinase-signaling pathways, inhibitors of lysine
deacetylases have emerged as a relevant cancer therapy. Vorinostat and
romidepsin are two HDAC inhibitors that have been approved for the treatment of
cutaneous T-cell lymphoma (Duvic et al., 2007; Piekarz et al., 2009). These
drugs and other HDAC inhibitors are currently in clinical trials for a wide array of
other cancers. Despite the success of vorinostat and romidepsin, the exact
mechanism by which these drugs elicit a positive therapeutic result has not been
fully elucidated. Epigenetic pathways have been proposed, and mutations of
acetyltransferases have furthermore been observed in some cancers (Yang,
2004). At the same time, it is conceivable that acetylation of non-histone
substrates may play a significant role in the regulation of cancer outcomes. For
example, acetylation has been observed on the tumor suppressor protein, p53.
Tang and colleagues demonstrated that loss of acetylation abolishes p53-
dependent growth arrest and apoptosis (Tang et al., 2008). Even more recently,
studies of the lysine acetylproteome have revealed thousands of lysine
acetylation sites on non-histone proteins. These proteins range include signaling
molecules, metabolic enzymes, and structural proteins suggesting many potential
routes whereby lysine acetylation may influence tumorigenesis (Choudhary et al.,
2009; Kim et al., 2006; Zhang et al., 2009; Zhao et al., 2010). Taken together,
these studies suggest that lysine acetylation is an important target for cancer
therapies, and that there are a number of novel targets of acetylation that may be
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regulated by therapeutic interventions targeting the modifiers and binding
domains for this critical protein post-translational modification.
Proteomics
In order to characterize signaling networks, a number of different
approaches have been utilized. Until the 1990s, many approaches relied on
probing a particular subset of proteins in a particular signaling network using a
wide range of biochemical techniques. The introduction of the microarray
ushered in an era of genomics and microarrays wherein alterations in the
transcript abundance of entire genomes could be queried simultaneously in
response to a variety of stimuli. While genome-wide profiling provided and
continues to provide a great abundance of knowledge, additional layers of
information provide a richer portrait of the underlying behavior of the biological
system of interest. With the introduction of electrospray ionization and matrix-
assisted laser desorption, "omics" based approaches could then quickly be
expanded to include mass-spectrometry based proteomics. In principle,
proteomics aims to identify the protein composition of a complex mixture of
proteins. These protein mixtures can be further reduced in complexity by taking
advantage of a variety of features of the protein: charge, size, hydrophobicity.
In addition to characterizing protein identity, recognizing that protein
activity can be regulated by post-translational modifications, a number of different
approaches have been suggested to enrich for subsets of the proteome. This
thesis focuses particularly on the tyrosine phosphoproteome and acetylproteome.
Efforts to profile the tyrosine phosphoproteome have been ongoing for more than
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a decade, and a number of strategies have been proposed to enrich for this low
abundance modification from complex mixtures. Many of these approaches rely
on affinity enrichment based on the biochemical features of phosphorylated
peptides or proteins. For example, immobilized metal affinity chromatography
(IMAC) and strong cation exchange (SCX) take advantage of the charged
properties of a phosphorylated peptide to separate the from non-phosphorylated
peptides (Beausoleil et al., 2004; Ficarro et al., 2002). Although these
techniques have been critical for enabling analysis of the phosphoproteome,
serine and threonine sites dominate the phosphoproteome, at >90% and >9%,
respectively (Hunter and Sefton, 1980). To access tyrosine phosphorylation from
this complex mixture, antibody enrichment is typically required. This modular
approach of antibody-based enrichment coupled with subsequent sample
fractionation provides a robust tool for the analysis of proteomes.
Quantitative Proteomics
Simply cataloging a list of proteins provides little functional insight into how
a particular biological response may be regulated. Quantifying how the
phosphoproteome responds to particular perturbations can reveal how a
signaling network responds to drug treatment or growth factor stimulation (Pan et
al., 2009; Zhang et al., 2005). Two of the most popular methods for proteomic
quantification include metabolic stable isotope labeling (e.g. stable isotope
labeling of amino acids in cell culture (SILAC)) and chemical isotope labeling
(e.g. isobaric tag for relative and absolute quantification (iTRAQ)). SILAC
labeling makes use of heavy amino acids that are introduced by culturing cells in
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cell culture media containing different heavy amino acids. After five or six
doublings in this media, protein labeling with the heavy amino acids is effectively
complete and quantification of these proteins can occur by comparing the relative
abundance of the peptide mass variants in a full scan mass spectrum (Figure 1-
6A). iTRAQ labeling of peptides results from a chemical modification of isobaric,
amine-reactive tags with a peptide's N-terminus and free amines on lysine.
These isobaric mass tags vary in the positioning of isotopically tagged atoms.
iTRAQ quantification occurs in MS2 mode when the labeled peptides are
subjected to fragmentation thereby releasing their distinctive reporter ions (Figure
1-6B).
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Figure 1-5: Quantitative Proteomic Strategies. Quantitative proteomics leverages isotopic
labeling of peptides and proteins, either in culture, or after. Quantitation is performed in MS1
mode (SILAC) or MS2 mode (iTRAQ).
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Both methods have their relative merits. Large amounts of protein can be
labeled at once using SILAC by increasing the total number of cells cultured
whereas iTRAQ labeling is done on proteins or digested peptides. On the other
hand, SILAC labeling cannot be used to profile clinical samples. Despite the
critiques of both methods, they have both been successfully utilized to profile
signaling in response to growth factors as well as elucidate the mechanism of a
variety of therapeutic compounds (Bantscheff et al., 2007; Pan et al., 2009; Wolf-
Yadlin et al., 2007).
Manual Validation of Mass Spectrometry Data
Despite the attractive nature of generating large-scale datasets using
proteomic-based approaches, it is important to recognize the challenges in
generating high-quality mass spectrometry datasets. After acquisition of mass
spectrometry data, these large data files are typically processed to produce a file
compatible with protein databases and then subjected to a database search.
These database searches utilize a diverse array of algorithms to attempt to
assign a particular MS/MS spectrum to a predicted MS/MS spectrum. However,
there are very few heuristics that further clarify score thresholds that accurately
distinguish correct from incorrect spectral identifications. The gold-standard
method for truly identifying and confirming an MS/MS identification involves
looking for co-elution of a synthetic peptide along with manual validation of the
MS/MS spectrum of the synthetic peptide. Manual validations involves
comparing each individual peak of the spectrum with a theoretical peak list, and
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ensuring that all abundant peaks can be assigned to one of these theoretical
peaks. Though time-intensive, manual validation ensures that the data that the
biology community uses to design experiments and understand the mechanisms
of particular behaviors is of the highest quality possible. Recently, a number of
software packages have been released that aid in the process of manual
validation (Curran et al., 2013; Lam et al., 2007; Martin et al., 2010).
Computational Analysis of Proteomic Datasets
The advent of quantitative proteomics has also generated a need for
computational approaches to comprehensively query these massive datasets to
look for trends and meta-data. Leveraging many of the tools for analysis of gene
expression analysis, a number of clustering approaches have also been used to
analyze proteomic datasets. In addition to clustering these quantitative
proteomic profiles, other approaches to reconstruct the network topology have
also been utilized (Huang and Fraenkel, 2009; Margolin et al., 2006; Sachs et al.,
2005). These approaches have made use of Bayesian or probabilistic modeling
to identify a potential network structure. Incorporating post-translational
modifications can be challenging using the approaches described above, as they
do not all incorporate information on protein-protein interactions in the context of
when a particular a protein is post-translationally modified. These challenges are
alleviated by the use of databases that identify potential kinase substrates as well
as other tools that make use of information about protein domains or any other
features that account for the sequence context of a particular modification
(Linding et al., 2008; Miller et al., 2008).
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Proteornic Profiling of Lysine Acetylation
Lysine acetylation has classically been associated with histone biology.
Until the mid-2000s, the vast number of examples of acetylation sites primarily
occurred on histones save for a few notable exceptions such as the tumor
suppressor p53 (Tang et al., 2008). The advancements that occurred at the
same time in the field of proteomics then allowed for the cataloging of hundreds
of lysine acetylation sites. Kim and colleagues performed the first study of this
scale in 2006 where an acetyllysine immunoprecipitation was performed on
fractionated HeLa cell lysates and subjected to tandem LC/MS-MS analysis
identifying hundreds of novel acetylation sites (Kim et al., 2006).
This approach would then become the standard approach for subsequent
acetylproteomic studies until 2009 when the first quantitative analyses were
published using SILAC quantification (Choudhary et al., 2009). In this study, the
authors profiled the acetylproteome-wide response to HDAC inhibitors,
suberoylanilide hydroxamic acid (SAHA) and MS-275 and demonstrated that
lysine acetylation occurs on a number of macromolecular complexes implicated
in the regulation of chromatin remodeling, cell cycle, nuclear transport, and actin
nucleation.
Lysine acetylation has recently been profiled in the context of cellular
metabolism suggesting another biological function in addition to transcriptional
control where lysine acetylation may play a major role. Zhao and colleagues
demonstrated in lysates derived from mouse livers that almost every enzyme
involved in gluconeogenesis, glycolysis, and other metabolic processes were
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acetylated (Zhao et al., 2010). To gain further insight into this discovery, the
authors demonstrated that the concentration of glucose and fatty acids
influenced the acetylation status of metabolic enzymes. Lastly, the authors
demonstrated the functional consequence of lysine acetylation on particular
proteins. For example, they demonstrated that acetylation activated malate
dehydrogenase in the TCA cycle. Similarly, Wang and colleagues demonstrated
similar results in Salmonella (Wang et al., 2010). Here, the authors
demonstrated that central metabolism enzymes were heavily acetylated and
differentially utilized in response to different carbon sources. These changes
were concordant with changes in metabolic flux and cell growth. These two
studies set the stage for an emergent role for acetylation in the regulation of cell
metabolism.
Subsequent analyses of the acetylproteome have explored the effects of
loss of particular sirtuins, such as SirT1 and SirT3, or have explored the post-
translational modification in the context of a particular organism such as X (Chen
et al., 2012; Sol et al., 2012; Zhang et al., 2009). While many of the quantitative
studies have relied on approaches such as SILAC making it challenging to profile
tissue samples, Denu and colleagues recently expanded the mass spectrometry
technique to include isobaric mass tagging via the tanden mass tag (TMT)
reagent (Hebert et al., 2013; Thompson et al., 2003). Taken together, these
studies demonstrate a significant role for lysine acetylation in regulating a variety
of biological activities. These studies demonstrate the utility of robust tools and
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strategies to profile acetyllysine signaling to gain insight into how it may influence
disease etiology and integrate into broader signaling networks.
As these quantitative mass spectrometric approaches to profile the
acetylproteome continue, they must also be complemented with efforts to
characterize the functional consequence of lysine acetylation on a particular
protein, and on a specific site. This information will allow scientists to gain further
insight into the dynamic regulation of this post-translational modification and how
it regulates cell behavior.
Tools to Enrich for the Acetylproteome
The acetylproteome experiments described above relied on the availability
of an antibody to enrich for acetylated proteins from a complex mixture of
peptides. A typical experimental protocol involves the incubation of lysate and
antibody overnight, followed by a series of wash steps, and finally an elution.
Proteins are then visualized using western blotting, and peptides are typically
analyzed on a mass spectrometer. While this approach is the most popular, it is
subject to variability depending on the antibodies and wash buffers used.
Non-antibody based approaches have also been proposed. Andersen
and colleagues utilized a modified form of the biotin switch assay (Andersen et
al., 2011). Here, the authors exchanged the acetyl group with a biotin tag taking
advantage of in vitro deacetylation reactions and an amine reactive biotin tag.
Using streptavidin beads, the authors recovered formerly acetylated proteins
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from this complex mixture, and then analyzed these peptides using mass
spectrometry.
Protein domains have been used as affinity enrichment tools for profiling
post-translational modifications; however, they have not been utilized for
acetyllysine. Machida and colleagues pioneered many of these approaches using
phosphotyrosine-binding domains (Machida et al., 2003, 2007). Here the authors
used recombinant SH2 domains to enrich for tyrosine phosphorylation proteins
from complex mixtures. These successes suggest that it may be possible to
utilize bromodomains as a tool to enrich for acetylated proteins and peptides
from a complex mixture.
For some proteins, affinity enrichment to identify acetylated proteins and
peptides has not been necessary. Top-down proteomics have allowed
researchers to profile intact histones for potential modifications; however, this
approach can be confounded by the combinatorial explosion of potential
combinations of post-translational modifications that can occur on these proteins.
Enzyme Substrate Profiling
While proteomic approaches to profile post-translational modifications can
reveal how networks respond to a variety of exogenous stimuli or cellular
perturbations, these experiments provide little insight into the mechanisms that
drive a particular quantitative pattern of acetylation or phosphorylation. For
example, the observation that a particular protein is hyperacetylated does not
indicate what acetyltransferase or deacetylase may be responsible for the
observed behavior. In some cases, mining the literature, either manually or
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computationally, can provide insight into what enzymes may modify a particular
protein substrate; however, in many cases this information does not exist (Li et
al., 2012). Despite the battery of tools at our disposal to identify enzyme-
substrate interactions, this identification is often confounded by the complex
nature of biological systems: a protein may be modified by more than one
enzyme at the same residue; some enzymes may compensate for one another in
genetic knockdown experiments, and complex signaling networks and feedback
loops may confound hypotheses.
Chemical genetic approaches have been proposed to identify kinase
substrates. The most popular of these approaches, pioneered by Shokat (Shah
et al., 1997), involves the introduction of a mutation to the gatekeeper residue of
the ATP binding pocket of a particular kinase, thereby allowing the kinase to
accommodate a bulkier ATP analog. Labeled substrates can then be identified
using a radiolabeled or gamma-thiol-phosphate ATP analog.
Approaches to profile the substrates of acetyltransferases have made use
of similar bio-orthogonal strategies. Yu and colleagues utilized chloro-acetyl-CoA
as an acetyl-CoA analog to identify substrates of Gcn5, while Yang and
colleagues utilized 4-pentynoyl-CoA as an acetyl-CoA analog to identify potential
p300 substrates (Yang et al., 2011; Yu et al., 2006). These approaches differ
from the Shokat method insofar that no mutation is introduced to the
acetyltransferase. The lack of a mutation that enables only one, or in some cass
a subset of enzymes to utilize the analog, may greatly increase the potential for
non-specific utilization of the acetyl-CoA analog by other enzymes.
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Background utilization of the analogs by enzymes other than the enzyme
of interest is an important challenge to consider when identifying substrates. To
address this challenge, Carlson and colleagues combined the Shokat method
with SILAC labeling to distinguish background labeling from specific labeling by
ERK2 (Carlson et al., 2011). This quantitative method of substrate labeling
allows for quantification of kinase substrate utilization under a variety of
conditions. Similarly, this approach could be extended to the study of lysine
acetyltransferases. Since, it has also been demonstrated that the reagents used
for the identification of lysine acetyltransferase substrates can be non-specifically
utilized by a wide variety of enzymes, quantitative methods will be necessary for
the identification of acetyltransferase substrates as well.
Motivation
Cellular signaling networks make use of post-translational modifications to
transfer information throughout the network. The role of particular post-
translational modifications have been demonstrated in regulated a variety of
cellular responses. Most commonly, the post-translational modification of
interest has been tyrosine phosphorylation given the connection between
receptor tyrosine kinase signaling and a wide array of responses such as growth,
migration, and proliferation. Despite the immense focus on tyrosine kinase
signaling in the context of cellular signaling networks, it has been demonstrated
that perturbations applied to other enzymes, specifically, the histone
deacetylases, can influence cellular responses both in vitro in the case of insulin
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signaling as well as in patients with the use of HDAC inhibitors to treat patients
with CTCL.
Despite these discoveries, our understanding of how perturbation of lysine
acetylation broadly integrates with cellular signaling networks, specifically
phosphotyrosine signaling, to drive these outcomes is piecemeal at best. To
address this challenge, in the second chapter of this thesis, I will describe the
development of a method to query phosphotyrosine signaling dynamics and
lysine acetylation dynamics from the same sample. Application of this method to
growth factor stimulated cells revealed a surprising result demonstrating
interconnectivity between tyrosine phosphorylation networks and lysine
acetylation networks. In the third and fourth chapters of this thesis, I describe
the development of a suite of tools to quantitatively probe the acetylproteome,
focused mainly on enrichment of acetylated peptides and proteins from complex
mixtures as well as identifying lysine acetyltransferase substrates. In the fifth
and sixth chapters of this thesis, I describe computational efforts to deal with two
challenges in discovery-based proteomics: manual validation of MS/MS spectra
and missing data in mass spectrometry datasets. Lastly, I conclude with a
discussion of future directions for this project, and the implications for this work in
the context of cellular signaling.
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Chapter 2 : Quantitative Profiling of Lysine
Acetylation Networks and their Crosstalk with
Tyrosine Phosphorylation
Introduction
Long thought to be primarily restricted to histone modification, in the past
decade lysine acetylation has emerged as a proteome-wide post-translational
modification rivaling phosphorylation in scale and biological relevance
(Kouzarides, 2000; Norvell and McMahon, 2010). High-resolution mass
spectrometry has enabled the identification of thousands of novel lysine
acetylation sites, greatly expanding the lysine acetylproteome beyond
transcriptional control to include proteins involved in both signaling and
metabolism (Choudhary et al., 2009; Kim et al., 2006; Wang et al., 2010; Zhang
et al., 2009; Zhao et al., 2010). The clinical relevance of lysine acetylation has
also been demonstrated, as histone deacetylase inhibitors (HDACi's) such as
vorinostat (suberoylanilide hydroxamic acid (SAHA)) and romidepsin (FK228) are
approved for the treatment of cutaneous T-Cell lymphoma (CTCL) and are
undergoing clinical trials for a number of other cancers (Johnstone, 2002; Mann
et al., 2007; Piekarz et al., 2009). Despite the clinical success of these
compounds, the mechanism by which these inhibitors function to mediate growth
alterations observed in certain cancers or cell lines is poorly understood.
Although changes in histone acetylation were originally thought to drive a
transcriptional program that underlies response to HDACi, the discovery of lysine
acetylation sites on non-histone proteins suggests the potential for non-
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transcriptional mechanisms that drive therapeutic response (Khan and La
Thangue, 2012; Xu et al., 2007). Even as the biological and clinical relevance for
lysine acetylation is being uncovered, most of the oncogenic phenotypes, such
as increased mitogenesis, migration, invasion, and therapeutic resistance, have
historically been ascribed to the aberrant protein phosphorylation signaling
cascades driven by altered expression, mutation, or activation of protein kinases
and phosphatases (Blume-Jensen and Hunter, 2001; Downward, 2003; Hanahan
and Weinberg, 2011; Irish et al., 2006). To map the specific phosphorylation sites
associated with these phenotypes, a plethora of systems-level studies have
accompanied decades of molecular biology to profile the phosphorylation
signaling in cancer cells and tumors under a variety of conditions, revealing
features such as the temporal evolution of these signals as well as diversity in
the temporal responses to ligand stimulation (Rikova et al., 2007; Wolf-Yadlin et
al., 2006). While the connection between dysregulation of kinase signaling and
cancer is well established, relatively little is known regarding the link between
lysine acetylation and kinase signaling, despite the use of HDACi's as anti-
cancer therapeutics. To this end, the interaction between phosphorylation and
acetylation has primarily been explored at the single protein level, most
commonly in studies of the histone code but also on signal transducers and
activators of transcription (STAT) proteins and the tumor suppressor p53, among
others (Kramer et al., 2009; Li et al., 2008; Nie et al., 2009; Tang et al., 2008).
These studies have highlighted functional interactions in which each modification
affects the biological consequence of the other modification. Bioinformatic
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approaches to analyzing the interaction of protein phosphorylation and lysine
acetylation at the network level have also been performed, but have been largely
limited to cataloging the overlapping proteins identified in large-scale datasets of
either modification, with minimal functional information arising from these studies
(Noort et al., 2012). The link between oncogenic signaling from RTKs and lysine
acetylation has not been systematically explored in cancer cells, yet such a study
may hold a wealth of insight into the mechanisms by which HDAC inhibitors act
to alter phenotypic outcomes both in vitro and in vivo. To explore the effect of
RTK activation on lysine acetylation at a network level, we profiled the dynamic
acetylation profiles of a variety of cancer cell lines in response to ligand activation
by different RTKs. Our data demonstrate that growth factor stimulation can
induce dramatic and surprisingly rapid changes in lysine acetylation across the
acetylproteome, suggesting a novel link between tyrosine phosphorylation and
altered lysine acetylation. These results suggest multiple post-translational
modification signaling networks engaging a wide and diverse array of proteins
may be involved in defining the cellular responses to exogenous stimulation, and
provide insight as to how HDACi's may rewire the tyrosine phosphorylation
signaling response to RTK activation.
Results
Class 1111 HDAC inhibitor and EGFR-inhibitors reduce cell growth.
To investigate the effects of HDAC inhibition on NSCLC cells, A549 cells
were treated with a panel of inhibitors, including those targeting Class I/1l
HDACs, Class Ill HDACs (Sirtuins), and the receptor tyrosine kinase EGFR.
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Briefly, 100K cells were seeded in 6-well dishes. Cells were then treated with a
panel of inhibitors: 10 pM TSA targeting Class 1/11 HDACs, 5 mM nicotinamide
targeting sirtuins, 10 pM gefitinib targeting EGFR, and 500 nM CUDC-101
targeting both EGFR and Class 1/11 HDACs. Cell counts were measured at 24,
48, 72, and 96 hours. Experiments were performed in triplicate, and results are
shown in Figure 2-1. 5 mM nicotinamide was the least effective at reducing cell
growth, while all other inhibitor treatments greatly reduced cell growth. The
combination of TSA and gefitinib appears to be the most effective at reducing cell
growth at early timepoints, though the difference is not statistically significant. By
day 4, CUDC-1 01, TSA, gefinitib, and the TSA-gefitinib combination had
approximately reduced cell growth to similar extents.
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Figure 2-1: Growth Curves of Inhbitor-Treated A549 Cells. A549 cells were treated with a panel
of inhibitors targeting both EGFR and HDACs, and their growth was measured at 0, 24, 48, 72,
and 96 hours.
Insulin stimulation induces rapid lysine acetylation changes in
hepatocellular carcinoma cells.
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To investigate the effects of receptor tyrosine kinase activation on protein
lysine acetylation, we stimulated the hepatocellular carcinoma cell line, HepG2,
with insulin for 0, 1, 5, and 30 minutes. At the appropriate time points, cells were
rinsed, lysed in 8M urea, and proteins were reduced, alkylated, and digested with
trypsin. Samples were isotopically labeled with iTRAQ for quantitative MS
analysis. iTRAQ-labeled peptides were isolated by immunoprecipitation with
anti-acetyllysine antibodies and analyzed by reverse-phase LC-MS/MS (Figure 2-
2).
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Figure 2-2: Quantitative Mass Spectrometry Protocol. HepG2 cells were stimulated for 0, 1,
5, and 30 minutes with 150 nM insulin and then lysed in 8M urea. Lysates were reduced,
alkylated, and trypsin-digested. Peptides were then differentially labeled with iTRAQ.
Acetyllysine enrichment was performed by peptide immunoprecipitation using anti-acetyllysine
antibodies prior to LC-MS/MS analysis. Peptides were identified using CID scans and quantified
using their corresponding HCD scans.
This analysis led to the identification of 45 unique acetyllysine-containing
peptides on 31 proteins across triplicate analyses. Within a minute of insulin
stimulation, a variety of lysine acetylation sites showed dramatic changes in their
level of modification, a result previously undocumented in the literature. To
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visualize the network-level response of the HepG2 cells to insulin stimulation and
group peptides with similar temporal responses, we clustered the dynamic
acetylation profiles using a combined affinity propagation-hierarchical clustering
algorithm (Figure 2-3).
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Figure 2-3: Heatmap of lysine acetylation dynamics in response to insulin in HepG2 cells.
Heat map representing the log2 fold-change relative to the unstimulated condition of the 44
acetylation sites quantified across three biological replicates. Time points are indicated at the
bottom of the heat map. Acetylation profiles were clustered using a combined affinity propagation-
hierarchical clustering algorithm to group acetylation sites demonstrating similar temporal
dynamics.
As can be seen in Figure 2-3, although acetylation dynamics at various
sites covered a range of responses, multiple clusters of similarly regulated
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acetylation sites were present in the data. Cluster 1, for example, is
characterized by a rapid deacetylation that is sustained over the course of insulin
treatment. In contrast, clusters 2 and 3 are characterized by a rapid increase in
acetylation at 1 minute followed by a rapid deacetylation that attenuates to near-
unstimulated levels. Other sites remained relatively unchanged for the duration of
the insulin stimulation. Clustering may reveal shared pathways or previously
undefined roles for many of these acetylation sites and proteins in the cluster.
Although the number of sites per cluster was limited, analysis of cluster 1
revealed enrichment for proteins involved in transcriptional control including
histones. The role of many of these sites identified in this analysis remains
uncharacterized, however it is interesting to note that multiple sites on related
proteins are regulated similarly, potentially indicating a concerted response or
activation/inhibition of a given enzyme associated with each of the proteins.
To better understand the regulation of acetylation dynamics, we selected a
subset of proteins on which we had identified multiple acetylation sites.
Comparing the acetylation dynamics across multiple sites on the same protein
revealed that acetylation dynamics are, in some cases, site-specific and not
simply an affect of altered protein expression or stability at the selected time
points. For example, histone H3 shows a diverse set of responses depending on
the site modified (Figure 2-4a) while the acetylation sites measured on
remodeling and spacing factor 1 are both characterized as increasing in
acetylation at 1 minute followed by a decrease in acetylation thereafter (Figure 2-
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4b). Taken together, these data demonstrate that lysine acetylation can be
rapidly regulated in response to insulin stimulation.
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Figure 2-4: Acetylation Dynamics on Proteins with Multiple Acetylation Sites (A) Acetylation
dynamics on histone cluster 1, H2b were measured in response to insulin stimulation. (B)
Acetylation dynamics on remodeling and spacing factor 1 were measured in response to insulin
stimulation.
IGF-1 and EGF stimulation induces rapid lysine acetylation changes in a
NSCLC line.
To determine whether the observed rapid acetylation dynamics were a
general dynamic response present in multiple cell lines under different
stimulation conditions, we next measured the acetylation responses of A549 non-
small cell lung cancer (NSCLC) cells stimulated with IGF-1 and EGF. We
stimulated A549 cells with 100 ng/mL IGF-1 and EGF for 0, 1, 5, and 30 minutes.
Lysates were prepared in the identical manner as before except lysates were
labeled with the 8plex iTRAQ reagent for simultaneous comparison of EGF and
IGF-1 stimulated lysates within the same MS analysis. This analysis led to the
identification of 91 unique acetyllysine-containing peptides on 61 proteins across
triplicate analyses of biological replicates. As we had previously seen in HepG2
52
cells stimulated with insulin, rapid acetylation dynamics were also observed in
response to both EGF and IGF-1 stimulation of A549 cells (Figure 2-5). These
data demonstrate that dynamic lysine acetylation occurs broadly in a wide array
of cell lines in response to a diverse set of receptor tyrosine kinase ligands. To
identify shared temporal responses among different acetylation sites as well
identify acetylation sites that show different responses in response to EGF or
IGF-1 stimulation we applied the combined affinity propagation-hierarchical
clustering algorithm. A multi-cluster response was detected, with several sites
showing a rapid decrease that was sustained across the entire length of EGF or
IGF-1 treatment, while other sites showed a rapid increase immediately following
stimulation followed by a decrease to basal levels. As expected, not all sites are
responsive to growth factor stimulation at these time points or concentrations;
accordingly, many sites did not respond to EGF or IGF-1 stimulation.
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Figure 2-5: Quantitative acetyllysine profiling of A549 cells stimulated with EGF or IGF-1.
This heat map shows the 90 acetylation sites quantified across the triplicate MS analyses. Time
points are indicated at the bottom of the heat map, and the ligand is indicated at the top of the
heatmap. The heatmap presents the fold change relative to the unstimulated condition and is
log2 transformed. Acetylation profiles were clustered using a combined affinity propagation-
hierarchical clustering algorithm to group acetylation sites demonstrating similar temporal
dynamics.
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It has been previously demonstrated that stimulation with different RTK
ligands can yield different tyrosine phosphorylation profiles indicating RTK
specific phosphorylation network utilization (Wolf-Yadlin et al., 2006). To
determine whether these novel, rapid, acetylation dynamic responses are also
differentially activated by stimulation with different RTK ligands, we compared the
temporal acetylation profiles of A549 cells stimulated with either EGF or IGF-1.
As can be seen in the heatmap in Figure 2-5, while the overall response to
stimulation is similar for the two ligands, there are particular acetylation sites that
demonstrate a differential response to the two RTK ligands.
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Figure 2-6: Comparison of Acetylation Dynamics between Proteins. A subset of proteins are
highlighted here to emphasize the diversity in acetylation responses. Some acetylation sites
show similar trajectories in a ligand-independent manner while others do not.
The temporal dynamics of three sites are highlighted in Figure 2-6 to
emphasize the diversity in acetylation responses. For example, ryanodine
receptor 3 shows an increase in acetylation over time when following EGF
stimulation while acetylation levels are reduced over time when treated with IGF-
1. Histone H3 shows similar temporal responses between both ligands, and K14
on complexin 1 shows increased acetylation followed by subsequent decreases
for both ligands, although the magnitude and dynamics differ. These data
suggest that receptor tyrosine kinase activation differentially drives acetylation
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dynamics, indicating that the observed acetylation dynamics are not simply a
general response to cell perturbation. The observed crosstalk between receptor
tyrosine kinases and lysine acetylation suggests a broader integration between
these two post-translational modifications.
Histone Deacetylase Inhibition Rewires Phosphotyrosine Signaling
Networks
Crosstalk between phosphotyrosine signaling networks and lysine
acetylation has typically been restricted to the study of individual proteins and not
the entire network. For example, one early demonstration of crosstalk between
lysine acetylation and tyrosine phosphorylation was first demonstrated on insulin
receptor substrate protein 2 (IRS2). Two groups demonstrated in different cell
lines that in the absence of ligand stimulation that IRS2 is acetylated (Li et al.,
2008; Zhang, 2007). Upon ligand stimulation (either insulin or IGF-1), the
authors both demonstrated that acetylation decreases on the receptor and
phosphorylation increases. Another example of acetylation-phosphorylation
crosstalk occurs on STAT3, where the authors demonstrated that the four
proximal lysines to Tyr705 were acetylated, and that in order to induce maximal
phosphorylation of Tyr705, all four lysines need to be acetylated (Nie et al.,
2009). These studies demonstrate crosstalk between these two modifications on
the protein level; however, to date, this crosstalk has not been demonstrated at
the network level.
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In order to profile this behavior at the network level, we first compared the
phosphotyrosine networks of A549 cells treated with the histone deacetylase
inhibitor, trichostatin A, which inhibits class 1/11 histone deacetylases. Briefly,
A549 cells were washed with warm PBS and then serum starved overnight. Prior
to lysis, cells were treated with 1 pM TSA or vehicle for one hour. Cells were
then lysed for quantitative mass spectrometry analysis, with four biological
replicates quantified for each condition as described previously. After manual
validation of the data, iTRAQ intensities representing the four biological
replicates across the two conditions were normalized to the yielding 45
phosphotyrosine-containing peptides on 34 proteins. We identified four
phosphorylation sites that were statistically different between the two conditions,
p<0.05, (Figure 2-7). Of these four sites, pTyr798 on PTPRA has been
suggested to regulate its enzymatic activity, suggesting that TSA treatment may
alter signaling via this pathway (Lammers et al., 1998). The other three
phosphorylation sites are on proteins that play roles in modulating cell survival
and regulation of growth, although the function of the specific sites are poorly
characterized in the literature. While most studies on the effects of these
inhibitors have focused on much later time points, on the scale of many hours or
days, these data demonstrate that short-term inhibition of lysine deacetylases not
only perturb lysine acetylation levels as expected but also induces changes to
the phosphotyrosine signaling network.
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Figure 2-7: Quantitative phosphotyrosine profiling of A549 cells treated with HDAC
inhibitor, TSA. Four phosphotyrosine sites were found to be significantly (p<0.05) differentially
phosphorylated between A549 cells treated with TSA or DMSO. Average phosphorylation levels
are represented. Error bars indicate standard error.
We next profiled the effects of TSA treatment on the EGF phosphotyrosine
signaling network. Again, A549 cells were serum starved overnight and
subsequently treated with 1 pM TSA or vehicle for an hour. After the hour, cells
were stimulated with 100 ng/mL EGF for 5 minutes, lysed and then prepared for
MS analysis. A total of 82 tyrosine phosphorylation sites on 64 proteins were
manually validated and quantified for four biological replicates per condition. To
quantify the magnitude of the effect of TSA on the response to EGF stimulation,
the ratio of the EGF-induced fold change in phosphorylation between vehicle and
TSA treated cells was calculated, which we refer to as the fold change ratio
(FCR). While many of the sites identified did not fall within the canonical EGF
signaling network, we mapped the mean FCR to those sites that did (Figure 2-8).
The FCR pathway map demonstrates that short-term TSA treatment rewires the
EGF signaling network, with some of the phosphorylation sites, such as pTyr354
on tensin 3 and pTyr844 on catenin delta 1, demonstrating large changes in their
EGF response (FCR < 0.3 and FCR >1.9). For many other phosphorylation sites
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in the canonical network, including EGFR phosphorylation sites, TSA pre-
treatment did not affect the phosphorylation response to EGF stimulation. These
data suggest that TSA pre-treatment affects specific components downstream of
the receptor within the EGFR pathway, potentially through altered acetylation on
these proteins, but does not appear to affect EGFR itself.
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Figure 2-8: Pre-treatment with TSA rewires the EGFR signaling network. The fold change
ratio in response to TSA treatment for four biological replicates is mapped to a visual
representation of the EGFR signaling network. The sites are color coded to characterize the
relative effect of TSA pre-treatment on the EGF response.
Understanding the mechanism underlying rapid acetylation dynamics
Identifying the mechanistic connections linking lysine acetylation dynamics
to receptor activation is difficult, especially since few, if any, models of the EGFR
signaling network incorporate elements of the lysine acetylation machinery into
their complex topologies. To begin to dissect the biomolecular underpinnings of
growth factor-driven lysine acetylation dynamics, we utilized experimental
approaches to explore the interplay between lysine acetylation and tyrosine
phosphorylation. These approaches included profiling both EGFR and IGF1 R,
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their post-translational modifications and interacting partners, as well as an
inhibitor screen to further explore how kinase inhibition alters signaling dynamics.
To gain added insight into the mechanism by which lysine acetylation
dynamics are driven by receptor tyrosine kinases, we profiled EGFR and IGF1 R
for post-translational modifications. Briefly, A549 cells were serum-starved
overnight and then stimulated with either 100 ng/mL EGF or IGF for one minute
prior to lysis. Lysates were then subjected to either an EGFR or IGF R protein
immunoprecipitation, and beads were boiled in laemmli buffer. Western blotting
was performed against the receptor, total phosphotyrosine, and total acetyllysine.
We observed the previously reported changes in phosphotyrosine signaling on
the receptors following ligand stimulation. Preliminary results suggest that IGFR
is acetylated, however, we were not able to measure changes in lysine
acetylation following stimulation or observe lysine acetylation of EGFR despite
literature reports of lysine acetylation of EGFR (Song et al., 2011). Lysine
acetylation of IGF1 R has not been reported in the literature but has been
identified in screens performed by Cell Signaling Technology (Hornbeck et al.,
2004).
In order to understand what elements of the lysine acetylation apparatus
may interact with EGFR, co-immunoprecipitation experiments were performed.
Briefly, unstimulated samples were mixed with antibodies against EGFR
overnight at 4*C. Washed protein G beads were added to the samples and
allowed to mix for another two hours. Samples were then rinsed four times with
RIPA buffer, and eluted using 8M urea. The eluent was subsequently reduced,
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alkylated, and digested with trypsin. Digested samples were acidified and loaded
directly onto a precolumn and analyzed using mass spectrometry.
Using this method, we were able to identify the acetyltransferases p300,
CBP, and MYST as potential interacting partners with EGFR. In this analysis, we
did not identify any deacetylases, although HDAC6 has been previously been
reported to interact with the receptor (Lissanu Deribe et al., 2009).
Mass Spectrometry-Based Inhibitor Screen
To continue our exploration for mechanisms that drive acetylation
dynamics, we employed a mass spectrometry-based inhibitor screen to
determine how inhibition of various kinases and deacetylases affect lysine
acetylation dynamics. The inhibitors tested in this section are by no means
exhaustive, but instead this section is intended to serve as a proof of principle by
which inhibitors can be utilized to explore network topologies.
Figure 2-9 illustrates a very simplified representation of the EGFR
signaling network with the addition of various components of the lysine
acetylation machinery. Activation of EGFR has been demonstrated to activate
the MAP kinase pathway in addition to the P13K pathway (Avraham and Yarden,
2011; Citri and Yarden, 2006; Yarden, 2001). Furthermore, given our
demonstration that receptor tyrosine kinase activation drives rapid deacetylation,
experiments were also performed to explore how inhibition of lysine deacetylases
influenced acetylation dynamics. Previous studies have demonstrated the utility
of mass spectrometry based approaches in profiling the mechanism of action of
various drugs. For example, Bantscheff and colleagues used a quantitative bead
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based proteomics platform to explore the effects of imatinib, an ABL kinase
inhibitor (Bantscheff et al., 2007). Pan and colleagues used a SILAC-based
platform to explore the effects of two MAP kinase inhibitors (U0126 and
SB02190) as well as a BCR-ABL inhibitor, dasatinib (Pan et al., 2009). In these
studies, the authors demonstrated both the power and potential of this
technology in exploring how kinase inhibition can influence signaling at the
network level.
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Figure 2-9: Simplified Schematic Diagram of the EGFR Signaling Network. EGFR signaling
activates two key pathways: the mitogen activated protein kinase (MAPK) pathway as well as the
phosphoinositide 3-kinase (P13K) pathway. Inhibitory arrows indicate there exists
pharmacological
To explore the effects of kinase or deacetylase inhibitors on acetylation
dynamics, A549 cells were serum starved overnight, and then treated with
kinase/deacetylase inhibitors or a vehicle control for 1 hour prior to EGF
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stimulation. The kinase inhibitors utilized included the MEK inhibitor, U0126,
P13K inhibitor, LY294002, and EGFR inhibitor, gefitinib. TSA was used as a
class 1/11 deacetylase inhibitor. Cells were subsequently stimulated with 100
ng/mL EGF for 5 minutes, and then lysed on ice with 8M urea. Lysates were
reduced, alkylated, and digested with trypsin and then labeled with 8plex iTRAQ
for quantitative mass spectrometry analysis. Kinase inhibitors were analyzed
together in an 8plex experiment, and deacetylase inhibitors were analyzed
together in an 8plex experiment. Acetyllysine peptide immunoprecipitations were
performed and the eluent from this immunoprecipitation was analyzed an
Orbitrap Elite mass spectrometer. The following experiments were performed as
a preliminary proof of principle (n=1).
As a very simple thought exercise, one can hypothesize a number of
different response models for acetylation dynamics in response to inhibitor
treatment. Broadly, these responses can be categorized into four different
categories: (A) EGF-independent/INH-independent, (B) EGF-independent/INH-
dependent, (C) EGF-dependent/INH-independent, and (D) EGF-dependent/INH-
dependent. Four hypothetical examples of these trends are shown in Figure 2-
10. It should be noted that there are a number of different permutations of the
examples shown in this figure, but these examples are intended as thought
models, and not the only examples of how these permutations may be manifest.
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Figure 2-10: Thought Model Prediction of Acetylation Dynamics in Response to Growth
Factor and Inhibitor Treatment. We hypothesized four different responses to combinatorial
treatment with inhibitors and growth factors. These bar graphs above are exemplars of each of
the four conditions.
We identified a number of acetylated peptides whose patterns conform to
three of these four models (Figures X through Z), however, examples of Model C
were not observed in the acetylation sites measured.
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Figure 2-11: Acetylation Dynamics on Histone H2B in response to Kinase Inhibition.
Histone H2B (K6/12/14/16/17/21) is relatively unaffected by inhibition of protein kinases.
Model B:
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Figure 2-12: Relative Acetylation of Histone H2B in response to HDACi, TSA. Histone H2B
acetylation (K13/16/17/21) is hyperacetylated in response to pre-treatment for one hour with TSA.
The site is relatively unresponsive to EGF treatment.
Model D:
Ribosomal Protein L24 (K37)
1.2
1-
C
0.8
0.6-
. 0.4
0.2
0-
DMSO GEF LY UO
0Control "EGF
Figure 2-13: Relative Acetylation of Ribosomal Protein L24 in Response to Kinase
Inhibition. Ribosomal Protein L24 acetylation (K37) is EGF responsive when treated with
DMSO; these dynamics are altered when the cells are pre-treated with kinase inhibitors.
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Figure 2-14: Relative Acetylation of Histone H2B in Response to HDACi, TSA. In the
absence of DMSO, EGF induces deacetylation of Histone H2B (K12/13/16). When pre-treated
with TSA, these dynamics are altered.
Discussion
To understand the potential connection between phosphotyrosine
signaling and altered lysine acetylation, we have quantified the immediate-early
temporal dynamics of lysine acetylation in response to growth factor stimulation.
To our surprise, many lysine acetylation sites displayed dramatic changes in their
level of modification within one minute of insulin stimulation of HepG2 cells,
highlighting a dynamic link between receptor tyrosine kinase signaling and lysine
acetylation, previously uncharacterized at the systems level. To assess whether
these rapid changes in lysine acetylation were specific to a particular cell line or
stimulation condition, we repeated these analyses in A549 NSCLC cells
stimulated with EGF or IGF-1 and identified similar rapid responses across
multiple lysine acetylation sites on many different proteins. Similar to tyrosine
67
phosphorylation networks downstream of different RTKs, some of the altered
acetylation sites display similar dynamics in response to either EGF or IGF-1,
while other acetylation sites are differentially regulated depending on the RTK
ligand. Clustering the dynamic responses of these sites has allowed us to
identify sub-clusters of acetylation sites that share similar temporal profiles,
suggesting that these proteins may fall within the same acetylation signaling
pathways. Taken together, these data strongly suggest that lysine acetylation is
a dynamic signaling process that occurs on a similar time scale to protein
tyrosine phosphorylation.
Most of the network-level studies of cell signaling have focused on
characterizing a particular aspect of the cellular response to a particular set of
stimulation conditions. For example, Wolf-Yadlin et al. and Blagoev et al. both
demonstrated that EGF stimulation of HMEC cells induces network-wide
changes in tyrosine phosphorylation at very short time scales (Blagoev et al.,
2004; Wolf-Yadlin et al., 2007). While these studies were novel in terms of
elucidating the speed and scale of the changes within the network, the fact that
there were rapid changes in tyrosine phosphorylation following RTK activation
was not novel. The analysis performed here demonstrates not only that
activation of a RTK induces changes in lysine acetylation but also demonstrates
that the time scale for these changes is as rapid as those demonstrated by
earlier studies of tyrosine phosphorylation dynamics. This result suggests an
interplay between protein tyrosine phosphorylation and lysine acetylation in a
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complex biochemical signaling network capable of controlling a diverse milieu of
cellular behaviors.
Phosphotyrosine profiling of cells treated with HDAC inhibitors reinforces
the complex relationship between these two dynamic post-translational
modifications. Our data demonstrates that short-term treatment with an HDAC
inhibitor modulates the response to EGF stimulation, establishing a link between
acetylation and the enzymes that regulate tyrosine phosphorylation. These novel
insights further reinforce the complexity involved in the regulation of cellular
responses while highlighting potential pathways in which perturbations to one
PTM signaling network may lead to subsequent changes in the other. Whereas
current models of RTK networks focus uniquely on a particular post-translational
modification, such as phosphorylation, in mediating signal transduction from the
RTK, it is clear from our results that future models of intracellular signaling
networks will have to consider the integration of protein phosphorylation and
lysine acetylation dynamics in governing the overall response to stimulation. The
expression level and activity of various protein acetyl transferases and
deacetylates may modulate the protein tyrosine phosphorylation signaling
network, providing differential response to receptor activation in different
contexts.
Another important feature of this discovery concerns the role that lysine
acetylation plays in regulating various cellular phenotypes as we identified lysine
acetylation on proteins involved in a diverse range of biological processes.
Lysine acetylation has long been synonymous with transcriptional control as
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acetylation alters chromatin structure and histone-DNA interactions. To this end,
we observed rapid acetylation dynamics on multiple sites on histone proteins
within one minute of EGF stimulation. How these changes might affect
transcription is yet to be determined, but results from the Yarden lab have
demonstrated altered expression of hundreds of genes within 20 minutes of EGF
stimulation (Amit et al., 2007). The potential connection between rapid dynamics
of histone acetylation and rapid transcriptional changes will be an interesting
avenue to pursue. In addition to transcriptional regulation, a number of studies
have now demonstrated that lysine acetylation occurs outside of histones and
includes structural proteins as well proteins involved in signaling and metabolism,
although the functional role of lysine acetylation on many of these proteins has
not been explored (Choudhary et al., 2009; Kim et al., 2006). Here we
demonstrate that the level of modification on many of these sites is rapidly
altered in response to RTK stimulation, providing the potential for expeditious
modulation of many cell processes following cell perturbation.
While this study has demonstrated that there exists a link between lysine
acetylation and tyrosine kinases, the exact mechanism by which EGF stimulation
drives acetylation dynamics remains poorly understood. Signaling pathway
diagrams of the EGF signaling network rarely include enzymes involved in
altering lysine acetylation, although several studies have suggested potential
links between the EGF signaling network and various acetyltransferases and
deacetylases. For instance, HDAC6 and EGFR have been shown to interact in a
modified yeast two-hybrid assay; this same study established a negative
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feedback loop in which HDAC6 is phosphorylated at Tyr570 and thereby
regulates EGFR endocytosis (Deribe et al., 2009). Another study showed that
EGFR can be acetylated by CBP (Song et al., 2011). These studies lay the
groundwork for a more integrated network that involves kinases, phosphatases,
acetyltransferases, deacetylases and a wide array of other enzymes and
scaffolding proteins. This assertion is supported by the TSA experiments where
short-term inhibition of a class of lysine deacetylases can drive alterations in
phosphotyrosine signaling in the basal state and in response to ligand
stimulation.
This study has highlighted that tyrosine kinase activation can lead to rapid
changes in lysine acetylation. This discovery suggests the existence of novel
pathways that link phosphotyrosine signaling with proteins known to regulate
lysine acetylation. More importantly, the temporal dynamics experiments and
subsequent experiment demonstrating feedback from lysine deacetylase
inhibition to phosphotyrosine signaling highlights novel avenues in which
therapeutic interventions may have a broader effect on signaling and the
subsequent cellular responses. These results suggest future studies that can
investigate the link between these two post-translational modifications as well as
the links between many more modifications. For instance, it is conceivable that
rapid changes in lysine acetylation may also lead to rapid changes in other lysine
post-translational modifications such as methylation and ubiquitylation, since
lysine can be the site of a number of different post-translational modifications.
Future studies should continue to focus both on the diversity of the perturbations
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that may alter these post-translational modification networks as well as the time
scale over which these responses may be regulated. Further characterization of
the specific function of these acetylation and phosphorylation sites will allow us to
link the temporal dynamics with a particular cellular response. Taken together,
the insight into intracellular signaling gained in this study, coupled with
biochemical analysis and computation will allow us to better understand the
mechanisms of a vast array of therapeutics as well as build a better portrait of the
complex signaling pathways that integrate to execute and control cellular
behavior.
Materials and Methods
Cell Culture and Stimulation
Human hepatocellular carcinoma cells HepG2 cells were cultured in
DMEM with 10% fetal bovine serum, 2mM glutamine, 100 units/ml penicillin, and
100 mg/mI streptomycin. Human non-small cell lung cancer A549 cells were
cultured in RPMI with 10% fetal bovine serum, 2mM glutamine, 100 units/mI
penicillin, and 100 mg/ml streptomycin. Prior to stimulation, cells were washed
briefly with PBS and then incubated in their respective serum-free media
overnight. A549 cells were then stimulated with 100 ng/mL EGF or IGF-1 for 0,
1, 5, and 30 minutes. HepG2 cells were stimulated with 150 nM insulin at the
same time points. After the respective time points, cells were lysed in 8M urea
on ice. For phosphotyrosine profiling experiments following TSA treatment, cells
were washed briefly with PBS and serum starved overnight. Cells were treated
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for an hour with 1 pM TSA or DMSO. For EGF stimulation experiments, cells
were stimulated with 100 ng/mL EGF for five minutes. All samples were lysed on
ice with 8M urea. Kinase inhibitor screens were performed similarly. A549 cells
were serum starved overnight, pre-treated with 10 pM inhibitor (UO126,
LY294002: Cell Signaling Technologies, Gefitinib: LCLabs) or vehicle for 1 hour
and then stimulated with 100 ng/mL EGF for 5 minutes and then lysed as above.
Cell Growth Curves
6 well untreated plates were seeded with 1OOK cells per well. They were
treated with either vehicle, 1 pM TSA, 5 mM TSA, 10 pM gefitinib, 500 nM
CUDC-101, or a cocktail of 10 pM gefitinib and 1 pM TSA simultaneously to
emulate the effects of CUDC-1 01. Cell counts were performed at 24, 48, 72, and
96 hours.
Sample Preparation and Peptide IP
Protein concentration was quantified using a BCA assay and samples
were reduced (10 mM DTT, 56*C for 1 hr) and then alkylated (50mM
iodoacetamide, room temperature in the dark for 1 hr). Urea was then diluted
with 100 mM ammonium acetate buffer pH 8.9, and proteins were digested with
trypsin (sequencing grade, Promega) at an enzyme/substrate ratio of 1:100
overnight at room temperature. Trypsin activity was quenched by adding glacial
acetic acid. Urea was removed from the samples by reverse phase desalting
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using C18 SepPak cartridges (Waters) and peptides were lyophilized and stored
at -80*C.
400 ug of each sample was reacted with one tube of either 4plex iTRAQ
(HepG2 analysis) or 8plex iTRAQ (A549 analysis) with each label representing
one time point. Lyophilized samples were dissolved in 30 uL of 500 mM
triethylammonium bicarbonate, pH 8.5, and the iTRAQ reagent was dissolved in
70 uL ethanol (4plex) or isopropanol (8plex). The solution containing peptides
and iTRAQ reagent were vortexed, incubated at room temperature for 2 hours
and concentrated to 40 uL. Samples for a particular time course analysis were
then combined and concentrated to completion. Peptides were then dissolved in
400 uL IP buffer (100 mM Tris, 100 mM NaCI, and 1% Nonidet P-40, pH 7.4) and
the pH was adjusted to 7.4 prior to immunoprecipitation
For phosphotyrosine immunoprecipitations, 60 ug of Protein G beads were
briefly rinsed with IP buffer and spun down. They were then resuspended in 200
uL of IP buffer and allowed to mix for 8 hours with a cocktail of anti-
phosphotyrosine antibodies at 4C (PT66: Sigma, PY-100: Cell Signaling
Technology, 4G10: Millipore). After 8 hours, the beads were spun down, rinsed
once with 400 uL IP buffer and then mixed with resuspended iTRAQ-labeled
peptides and allowed to mix overnight on a rotor at 4C.
For acetyllysine immunoprecipitations, 40 uL of beads with preconjugated
acetyllysine antibodies (Immunechem) were rinsed four times and then combined
with resuspended iTRAQ labeled peptides and incubated overnight at 40C with
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rotation. Beads were rinsed once with 400 uL of IP buffer and then four times
with 400 uL of rinse buffer (100 mM Tris, pH 7.4), and peptides were eluted into
70 uL of 100 mM glycine pH 2. Eluents were cleared using immobilized affinity
metal chromatography (IMAC) (Zhang et al., 2005). Peptides were loaded onto a
precolumn and were separated by reverse phase HPLC (Agilent) over a 150
minute gradient prior to electrospray into an Orbitrap Elite mass spectrometer
(Thermo Fisher Scientific). To correct for slight variations in protein loading, the
mean iTRAQ ratios for all proteins identified in each analysis was used to
normalize the data.
Protein Immunoprecipitation and Western Blotting
A549 cells were stimulated with 100 ng/mL EGF or IGF-1 for one minute,
rinsed briefly with cold PBS, and then lysed in RIPA buffer (150 mM NaCl, 5 mM
EDTA, 1% Triton X-100, 1% deoxycholate, 50 mM Tris, pH 7.4). Protein
concentrations were quantified using the BCA assay. For each
immunoprecipitation, one milligram of cell lysate was mixed with 20 pL of EGFR
or IGF1-R antibody (EGFR: Santa Cruz, IGF1-R: Cell Signaling Technology) and
incubated overnight at 4C with rotation. After antibody-lysate incubation, 40 pL
of washed Protein A or Protein G beads were added to the lysate and incubated
at 4C for 2 hours with rotation. After bead incubation, beads were spun down
and subjected to 4 washes with RIPA buffer. Beads were boiled in 2X laemmli
buffer for 5 minutes and then spun down in a benchtop centrifuge. Lysates were
then run out on an SDS page gel at 120V for 2 hours and then transferred to
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nitrocellulose for 2 hours at 1OOV. Blots were blocked with either 5% BSA or 5%
milk depending on the primary antibody. Blots were incubated with primary
antibodies at a 1:1000 dilution overnight at 4C with gentle rocking (EGFR & pan-
phosphotyrosine: Santa Cruz, IGF1-R & pan-acetyllysine: Cell Signaling
Technology). Blots were washed three times with TBS with 0.1 % Tween (TBS-
T), and then incubated with secondary antibodies, mouse or rabbit, at a dilution
of 1:10000 for one hour at room temperature. Blots were then rinsed again three
times, five minutes each wash, with TBS-T and then exposed to enhanced
chemiluminescent reagent (ECL) and then imaged using film.
Mass Spectrometry Based Identification of EGFR Interacting Proteins
A549 cells were serum starved overnight, rinsed briefly with cold PBS, and
then lysed in RIPA buffer (150 mM NaCI, 5 mM EDTA, 1% Triton X-100, 1%
deoxycholate, 50 mM Tris, pH 7.4). Protein concentrations were quantified using
the BCA assay. For each immunoprecipitation, one milligram of cell lysate was
mixed with 20 pL of EGFR antibody (EGFR: Cell Signaling Technology) and
incubated overnight at 4C with rotation. After antibody-lysate incubation, 40 pL
of washed Protein G beads were added to the lysate and incubated at 4C for 2
hours with rotation. After bead incubation, beads were spun down and subjected
to 4 washes with RIPA buffer. Bound proteins were eluted from the beads using
8M urea. The eluent was subsequently reduced with DTT, alkylated, and then
digested with trypsin overnight. The reaction was stopped by acid quenching
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and the sample was subsequently loaded directly onto a C18 precolumn, rinsed
with 0.2M acetic acid and then run on an Orbitrap Elite mass spectrometer.
Affinity Propagation Clustering Analysis
Quantitative acetylation site profiles across the 4 or 7 timepoints were
clustered using the affinity propagation algorithm proposed by Frey and Dueck
with a Euclidean distance similarity metric (Frey and Dueck, 2007).
Euclidean distance was used as the similarity metric between acetylation
profiles. Affinity propagation solutions, similar to other clustering algorithms, are
sensitive to the algorithm parameters selected by the user similar to the selection
of k in the k-means clustering algorithm. To address this critique, we constructed
a Gaussian mixture model based on the exemplar clustering solution. With
affinity propagation, the objective of the algorithm is to find exemplars that
maximize:
n--
max -IX ||_ - _zg
i=1E -
which can be transformed into a maximization of the log-probability of generating
the profiles from spherical-Gaussians centered at the exemplars:
21 dlogN(x.; ; 3 , o I) 2t.2 1 _jI2 d-log(27ro. 2)2or2 72
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The Gaussian mixture model is constructed as follows:
P(xi; 0) = f -^rN(ji; jj, 2 1)
jec
where {}Ec are the exemplars, frj is the number of profiles
assigned to exemplar xi, and
En&2 1 mn||I 
-Ig|2
i=1
is the overall mean squared distance from profiles to their
closest exemplars.
The resulting BIC criterion is:
n dim)
log P(Gi; 0) 2im(O) log(n)
i=1
where dim($) = |KId + IC - 1+ 1.
In this analysis, in the interest of computational time, self-similarity values were
iteratively varied, starting first with a large range of self-similarity values and
iterating over this range with a large step size, and then selecting a more narrow
range of self-similarity values with a smaller step size, ending with a step size of
0.5. BIC scores were calculated for each self-similarity value and the highest
scoring model was selected. An example of this iteration is shown in Figure X.
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Figure 2-15: Self-Similarity Range Finding The affinity propagation algorithm was applied
iteratively over a range of self-similarity values, initially over a large range with relatively large
step sizes and then iteratively reducing the range of self similarity values as well as the step size.
The starting self-similarity range was -100 to -2000 with a step-size of 100 and ended with a
range from -0.5 to 25 with a step size of 0.5.
Exemplars of the highest scoring model were then clustered using
hierarchical clustering and used to organize the full dataset in a hierarchical
format.
Statistical Analyses
T-tests were performed to compare the phosphorylation profiles of the
cells treated with or without TSA.
Mass Spectrometry Data Analysis
Raw mass spectrometry data files were converted into the .mgf format
using DTASupercharge 1.31 (http:// http://msquant.sourceforge.net/). All
resulting MS/MS spectra were searched against an NCBI 2009 Homo sapiens
database using Mascot version: 2.1.03 (Matrix Science). Trypsin enzyme
specificity was applied with a maximum of nine missed cleavages. Mass
tolerance was set at 10 ppm and fragment mass tolerance was set at 0.8 Da.
MS/MS spectra searches incorporated fix N-terminal iTRAQ and
carbamidomethylation of cysteine while incorporating variable modifications of
oxidized methionine, and acetylation of lysine or iTRAQ modification of lysine.
Precursor ions were manually validated for contamination (ions with intensity
>25% of the base peak within 1 m/z around the selected precursor ion) and
discarded if they exceeded the threshold as they may contribute to the relative
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iTRAQ intensities. MS/MS spectra were manually validated to confirm peptide
identification and acetylation site localization.
81
References
Amit, I., Citri, A., Shay, T., Lu, Y., Katz, M., Zhang, F., Tarcic, G., Siwak, D.,
Lahad, J., Jacob-Hirsch, J., et al. (2007). A module of negative feedback
regulators defines growth factor signaling. Nature Genetics 39, 503-512.
Avraham, R., and Yarden, Y. (2011). Feedback regulation of EGFR signalling:
decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 12, 104-
117.
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson,
S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007). Quantitative
chemical proteomics reveals mechanisms of action of clinical ABL kinase
inhibitors. Nat. Biotechnol. 25, 1035-1044.
Blagoev, B., Ong, S.-E., Kratchmarova, I., and Mann, M. (2004). Temporal
analysis of phosphotyrosine-dependent signaling networks by quantitative
proteomics. Nature Biotechnology 22,1139-1145.
Blume-Jensen, P., and Hunter, T. (2001). Oncogenic kinase signalling. Nature
411, 355-365.
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M.L., Rehman, M., Walther, T.C.,
Olsen, J.V., and Mann, M. (2009). Lysine Acetylation Targets Protein Complexes
and Co-Regulates Major Cellular Functions. Science 325, 834-840.
Citri, A., and Yarden, Y. (2006). EGF-ERBB signalling: towards the systems
level. Nat Rev Mol Cell Biol 7, 505-516.
Downward, J. (2003). Targeting RAS signalling pathways in cancer therapy.
Nature Reviews Cancer 3,11-22.
Frey, B.J., and Dueck, D. (2007). Clustering by Passing Messages Between Data
Points. Science 315, 972-976.
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of Cancer: The Next
Generation. Cell 144, 646-674.
Hornbeck, P.V., Chabra, I., Kornhauser, J.M., Skrzypek, E., and Zhang, B.
(2004). PhosphoSite: A bioinformatics resource dedicated to physiological
protein phosphorylation. Proteomics 4, 1551-1561.
Irish, J.M., Kotecha, N., and Nolan, G.P. (2006). Mapping normal and cancer cell
signalling networks: towards single-cell proteomics. Nature Reviews Cancer 6,
146-155.
82
Johnstone, R.W. (2002). Histone-deacetylase inhibitors: novel drugs for the
treatment of cancer. Nature Reviews Drug Discovery 1, 287-299.
Khan, 0., and La Thangue, N.B. (2012). HDAC inhibitors in cancer biology:
emerging mechanisms and clinical applications. Immunol. Cell Biol. 90, 85-94.
Kim, S.C., Sprung, R., Chen, Y., Xu, Y., Ball, H., Pei, J., Cheng, T., Kho, Y.,
Xiao, H., Xiao, L., et al. (2006). Substrate and functional diversity of lysine
acetylation revealed by a proteomics survey. Mol. Cell 23, 607-618.
Kouzarides, T. (2000). Acetylation: a regulatory modification to rival
phosphorylation? The EMBO Journal 19,1176-1179.
KrAmer, O.H., Knauer, S.K., Greiner, G., Jandt, E., Reichardt, S., Gohrs, K.-H.,
Stauber, R.H., Bohmer, F.D., and Heinzel, T. (2009). A phosphorylation-
acetylation switch regulates STAT1 signaling. Genes Dev. 23, 223-235.
Lammers, R., Moller, N.P., and Ullrich, A. (1998). Mutant forms of the protein
tyrosine phosphatase alpha show differential activities towards intracellular
substrates. Biochem. Biophys. Res. Commun. 242, 32-38.
Li, Y., Xu, W., McBurney, M.W., and Longo, V.D. (2008). SirT1 inhibition reduces
IGF-1/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab. 8, 38-48.
Lissanu Deribe, Y., Wild, P., Chandrashaker, A., Curak, J., Schmidt, M.H.H.,
Kalaidzidis, Y., Milutinovic, N., Kratchmarova, I., Buerkle, L., Fetchko, M.J., et al.
(2009). Regulation of Epidermal Growth Factor Receptor Trafficking by Lysine
Deacetylase HDAC6. Sci. Signal. 2, ra84.
Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R., and Pazdur, R. (2007). FDA
Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-
Cell Lymphoma. The Oncologist 12, 1247-1252.
Nie, Y., Erion, D.M., Yuan, Z., Dietrich, M., Shulman, G.I., Horvath, T.L., and
Gao, Q. (2009). STAT3 inhibition of gluconeogenesis is downregulated by SirT1.
Nature Cell Biology 11, 492-500.
Noort, V. van, Seebacher, J., Bader, S., Mohammed, S., Vonkova, I., Betts, M.J.,
KOhner, S., Kumar, R., Maier, T., O'Flaherty, M., et al. (2012). Cross-talk
between phosphorylation and lysine acetylation in a genome-reduced bacterium.
Molecular Systems Biology 8.
Norvell, A., and McMahon, S.B. (2010). Rise of the Rival. Science 327, 964-965.
83
Pan, C., Olsen, J.V., Daub, H., and Mann, M. (2009). Global Effects of Kinase
Inhibitors on Signaling Networks Revealed by Quantitative Phosphoproteomics.
Mol Cell Proteomics 8, 2796-2808.
Piekarz, R.L., Frye, R., Turner, M., Wright, J.J., Allen, S.L., Kirschbaum, M.H.,
Zain, J., Prince, H.M., Leonard, J.P., Geskin, L.J., et al. (2009). Phase 11 Multi-
Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As
Monotherapy for Patients With Cutaneous T-Cell Lymphoma. JCO 27, 5410-
5417.
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J.,
Lee, K., Reeves, C., Li, Y., et al. (2007). Global Survey of Phosphotyrosine
Signaling Identifies Oncogenic Kinases in Lung Cancer. Cell 131, 1190-1203.
Song, H., Li, C.-W., Labaff, A.M., Lim, S.-O., Li, L.-Y., Kan, S.-F., Chen, Y.,
Zhang, K., Lang, J., Xie, X., et al. (2011). Acetylation of EGF receptor contributes
to tumor cell resistance to histone deacetylase inhibitors. Biochem. Biophys. Res.
Commun. 404, 68-73.
Tang, Y., Zhao, W., Chen, Y., Zhao, Y., and Gu, W. (2008). Acetylation Is
Indispensable for p53 Activation. Cell 133, 612-626.
Wang, Q., Zhang, Y., Yang, C., Xiong, H., Lin, Y., Yao, J., Li, H., Xie, L., Zhao,
W., Yao, Y., et al. (2010). Acetylation of Metabolic Enzymes Coordinates Carbon
Source Utilization and Metabolic Flux. Science 327,1004-1007.
Wolf-Yadlin, A., Kumar, N., Zhang, Y., Hautaniemi, S., Zaman, M., Kim, H.-D.,
Grantcharova, V., Lauffenburger, D.A., and White, F.M. (2006). Effects of HER2
overexpression on cell signaling networks governing proliferation and migration.
Molecular Systems Biology 2.
Wolf-Yadlin, A., Hautaniemi, S., Lauffenburger, D.A., and White, F.M. (2007).
Multiple reaction monitoring for robust quantitative proteomic analysis of cellular
signaling networks. PNAS 104, 5860-5865.
Xu, W.S., Parmigiani, R.B., and Marks, P.A. (2007). Histone deacetylase
inhibitors: molecular mechanisms of action. Oncogene 26, 5541-5552.
Yarden, Y. (2001). The EGFR family and its ligands in human cancer. signalling
mechanisms and therapeutic opportunities. Eur. J. Cancer 37 Suppl 4, S3-8.
Zhang, J. (2007). The Direct Involvement of SirT1 in Insulin-induced Insulin
Receptor Substrate-2 Tyrosine Phosphorylation. J. Biol. Chem. 282, 34356-
34364.
84
Zhang, J., Sprung, R., Pei, J., Tan, X., Kim, S., Zhu, H., Liu, C.-F., Grishin, N.V.,
and Zhao, Y. (2009). Lysine Acetylation Is a Highly Abundant and Evolutionarily
Conserved Modification in Escherichia Coli. Mol Cell Proteomics 8, 215-225.
Zhang, Y., Wolf-Yadlin, A., Ross, P.L., Pappin, D.J., Rush, J., Lauffenburger,
D.A., and White, F.M. (2005). Time-resolved Mass Spectrometry of Tyrosine
Phosphorylation Sites in the Epidermal Growth Factor Receptor Signaling
Network Reveals Dynamic Modules. Mol Cell Proteomics 4,1240-1250.
Zhao, S., Xu, W., Jiang, W., Yu, W., Lin, Y., Zhang, T., Yao, J., Zhou, L., Zeng,
Y., Li, H., et al. (2010). Regulation of Cellular Metabolism by Protein Lysine
Acetylation. Science 327,1000-1004.
85
Chapter 3 : Engineered Bromodomains: Tools to
Probe the Acetylproteome
Introduction
To characterize the signaling that may occur in response to growth factor
stimulation and a wide array of perturbations, profiling dynamic regulation of
phosphorylation and other post-translational modifications of proteins has been
performed (Chen et al., 2012; Pan et al., 2009; Zhang et al., 2005). However,
given that post-translationally modified proteins are typically in lower abundance
than unmodified proteins, methods to enrich for these modified proteins and
peptides from complex mixtures are immensely important.
Depending on the character of the post-translational modification, a
number of different methods have been approached to purify these modified
substrates from a complex mixture. For phosphopeptides, different strategies
including immobilizied metal affinity chromatography (IMAC) and strong cation
exchange (SCX) take advantage of the unique charge character of
phosphorylated peptides for affinity enrichment (Beausoleil et al., 2004; Ficarro et
al., 2002). The main approach to study the acetylproteome has relied on
immunoprecipitation by anti-acetyllysine antibodies (Choudhary et al., 2009; Kim
et al., 2006), although recent approaches have been proposed that make use of
a modified form of the biotin switch assay (Andersen et al., 2011). In this
chapter, a new method for the enrichment of acetylated peptides and proteins is
proposed.
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For some proteins, affinity enrichment to identify acetylated proteins and
peptides has not been necessary. Top-down proteomics has allowed
researchers to profile intact histones for potential modifications. However, the
combinatorial explosion of potential combinations of post-translational
modifications that can occur may confound the results from this top-down
approach. Despite this critique, top-down proteomics has been used
successfully to identify novel acetylation sites on histone proteins in S. cerevisiae
as well as novel post-translational modifications such as lysine crotonylation
(Gardner et al., 2011; Tan et al., 2011).
In addition to top-down proteomics to identify acetyllysine-containing
proteins, alternate approaches have been employed, utilizing both biochemical
assays as well as classical immunoprecipitation methods. One biochemical
method employed was a modified form of the biotin switch assay. Briefly, the
authors blocked the free amines of a cytoplasmic fraction of cell lysate using an
NHS-ester thereby creating a mix of lysines with newly blocked amines or
previously acetylated lysines from the endogenous acetyltransferases. The
authors next perform an in vitro deacetylation reaction using SirT1 hoping to
identify potential SirT1 substrates. The newly revealed amines from the
deacetylation reaction are then reacted with a NHS-SS-Biotin tag and are
recovered from the complex mixture using streptavidin. Proteins are digested
and released from the beads using a reducing reagent allowing for subsequent
MS-MS analysis of the proteins. In this report, they specifically investigated the
acetylation of an isoform of 14-3-3, but also report a number of potential SirT1
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substrates as well making this an extensible platform for the identification of
acetylated proteins and acetylation sites. One concern regarding this
experimental approach is that the in vitro deacetylation reaction may introduce
experimental artifacts by allowing protein-protein interactions that may not occur
in vivo. Furthermore, previous studies have demonstrated that SirT1 has no
substrate specificity in vitro suggesting that the proteins deacetylated in this
assay may not be true SirT1 substrates (Blander et al., 2005).
Antibodies represent the most common approach for affinity enrichment of
acetylated proteins and peptides. A typical antibody-based affinity enrichment
experimental protocol involves the capture of the lysine acetylated peptide or
protein during an overnight incubation of lysate and antibody, followed by a
series of wash steps, and finally an elution. Proteins are then visualized using
western blotting, and peptides are typically analyzed on a mass spectrometer.
The success of these experiments depends on many different factors, including
easily controlled variables such as the wash steps and buffer formulations.
However, the most critical aspect of these experiments is the quality (e.g., affinity
and specificity) of the antibody raised against the acetyllysine modification. Anti-
acetyllysine antibodies, both monoclonal and polyclonal, have been raised
against either a generic acetyllysine containing peptide or protein or a specific
site in the case of histones and a subset of other proteins. Despite the
availability of anti-acetyllysine antibodies from a wide array of vendors, the ability
of these antibodies to broadly recognize acetylated proteins across the proteome
is highly variable (Figure 3-1).
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Figure 3-1: Variability of Anti-Acetyllysine Antibodies: Identical cell lysates were separated
on SDS-page gels, transferred to nitrocellulose, and then blotted with different pan-acetyllysine
antibodies.
To test the quality of several commercially-available anti-acetyllysine
antibodies, identical cell lysates were separated on SDS-page gels, transferred
to nitrocellulose, blotted with a variety of pan-acetyllysine antibodies overnight
and then visualized. Different banding patterns are observed among the different
antibodies suggesting that the ability of these acetyllysine antibodies to recognize
the modification is highly variable. This issue is further confounded by the
polyclonal nature of many of the antibodies, giving rise to lot-to-lot variability.
While proteomic studies of other post-translational modifications have benefited
from the existence of high affinity monoclonal antibodies, the affinity tools for
lysine acetylation are still being developed.
In addition to utilizing antibodies for affinity enrichment, other biochemical
approaches have used the native binding domains of the respective post-
translational modifications. There exists a diverse array of protein domains that
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naturally bind to the diverse milieu of post-translational modifications, making
these domains an attractive option for non-antibody-based affinity enrichment.
For example, SH2 and PTB domains bind phosphorylated amino acids,
chromodomains bind methyllysine, ubiquitin-interacting motifs bind ubiquitin.
Many approaches have utilized a variety recombinant phospho-binding domains
as tools to enrich for phosphorylated proteins and peptides. Machida and
colleagues developed a high-throughput assay for profiling tyrosine
phosphorylation using SH2 domains (Machida et al., 2003, 2007). Recognizing
the challenges in comprehensive characterization of the tyrosine
phosphoproteome, the authors decided to use recombinant SH2 domains as a
bait to purify tyrosine phosphorylated proteins from a complex mixture. This
approach was also applied by Blagoev and colleagues in a mass spectrometry
experiment where they used a GST-tagged form of the Grb2 SH2 domain to
purify phosphorylated proteins from EGF stimulated HeLa cell lysate (Blagoev et
al., 2003). With this approach, the authors identified many known interacting
proteins as well as many novel interactions including CD-59. Despite the
successful application of phosphoprotein binding motifs as affinity reagents, very
few studies have explored affinity tools for other post-translational modifications.
In addition to utilizing antibodies for affinity enrichment, other biochemical
approaches have used the native binding domains of the respective post-
translational modifications. There exists a diverse array of protein domains that
naturally bind to the diverse milieu of post-translational modifications, making
these domains an attractive option for non-antibody-based affinity enrichment.
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For example, SH2 and PTB domains bind phosphorylated amino acids,
chromodomains bind methyllysine, ubiquitin-interacting motifs bind ubiquitin.
Many approaches have utilized a variety recombinant phospho-binding domains
as tools to enrich for phosphorylated proteins and peptides. Machida and
colleagues developed a high-throughput assay for profiling tyrosine
phosphorylation using SH2 domains (Machida et al., 2003, 2007). Recognizing
the challenges in comprehensive characterization of the tyrosine
phosphoproteome, the authors decided to use recombinant SH2 domains as a
bait to purify tyrosine phosphorylated proteins from a complex mixture. This
approach was also applied by Blagoev and colleagues in a mass spectrometry
experiment where they used a GST-tagged form of the Grb2 SH2 domain to
purify phosphorylated proteins from EGF stimulated HeLa cell lysate (Blagoev et
al., 2003). With this approach, the authors identified many known interacting
proteins as well as many novel interactions including CD-59. Despite the
successful application of phosphoprotein binding motifs as affinity reagents, very
few studies have explored affinity tools for other post-translational modifications.
Results
To investigate the potential of these domains as a means to enrich for
acetylated peptides, we generated fourteen N-terminally GST-tagged and C-
terminally His-tagged bromodomains representing all yeast bromodomains.
Bromodomains are observed on a diverse array of proteins, ranging from
proteins involved in chromatin remodeling and enzymatic activity (Figure 3-2).
Furthermore, these bromodomains have diverse histone binding preferences as
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demonstrated via histone protein and peptide binding assays (Zhang et al.,
2010). Likewise, other domains that bind covalent modifications such as SH2
and PTB domains also have diverse binding preferences (Liu et al., 2010).
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Figure 3-2: Yeast Proteins Containing Bromodomains. 9 yeast proteins contain
bromodomains. These proteins are diverse with respect to their length, number of
bromodomains, and domain composition.
As the bromodomains selected in this study have diverse amino acid
sequences, we first assessed whether the sequence diversity gives rise to
binding diversity (Figure 3-3).
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Figure 3-3: Bromodomain Amino Acid Sequence Alignment.
Since recent studies of the acetylproteome have demonstrated that lysine
acetylation occurs on a vast array of proteins in addition to histones, we
employed a generic strategy to explore bromodomain binding using a degenerate
peptide library array. 11-mer peptides were spotted onto the array with the
central position and one other position fixed, leaving the remaining positions
degenerate. In these experiments, the central position was lysine, either
acetylated or unacetylated, and the remaining positions were any of the 20
natural amino acids as well as pS, pT, pY, MeK, and AcK (Figure 3-4). In
addition to the degenerate array, histone peptides (either acetylated or
unacetylated) were spotted as controls.
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Figure 3-4: Degenerate Peptide Array Design. 1 1-mer peptides are spotted onto the array with
the central position and one other position fixed leaving the remaining positions degenerate. On
this array, peptides on the top half of the array have the central position fixed as acetyllysine, and
those on the bottom have the central position fixed as unacetylated lysine. Control histone
peptides were also spotted on the array.
To assess binding preferences, purified bromodomains were incubated
with a degenerate peptide membrane (Figure 3-4). Bound bromodomains were
transferred to nitrocellulose, and the membrane was subsequently incubated with
an anti-GST HRP-linked antibody and visualized using LICOR (Figure 3-5).
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Figure 3-5: Bromodomain Binding Assay (BBA). GST-tagged bromodomains are incubated
with a degenerate peptide array. After an hour of incubation, bound bromodomains are
transferred to nitrocellulose membranes. These nitrocellulose membranes are subsequently
blocked, incubated with an anti-GST primary antibody and then a fluorescent secondary antibody.
The bromodomain binding assay was initially utilized to query the
specificity of the second bromodomain from BDF1, bromodomain containing
factor 1. Using this approach, we observed that BDF1 binds to acetylated
peptides in a position-independent manner (Figure 3-6). At this dose of 50 nM,
the bromodomain appears to show little preference for particular amino acids,
though negatively charged amino acids (aspartic acid and glutamic acid) as well
as the phosphorylated residues appear to bind slightly weaker.
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Figure 3-6: Bromodomain Containing Factor 1, Second Bromodomain (BDF1-B)
Degenerate Peptide Array Results. BDF1-B was incubated with the degenerate peptide array
at a concentration of 50 nM. Unbound bromodomain was washed off; bromodomains were
transferred to a nitrocellulose membrane and incubated with an anti-GST antibody and visualized
using LICOR.
Performing the bromodomain-binding assay at a variety of doses reveals
an interesting dose response of these bromodomains. At low doses, a slight
preference for glycine and lysine can be observed for BDF1-B (Figure 3-7) and at
higher concentrations of bromodomains, binding of the unacetylated library is
also detectable. This suggests that bromodomains are capable of binding a
diverse array of peptides. Without knowing the exact concentration of the
bromodomain inside the cell, it is hard to predict what substrates the
bromodomain may be binding to. This is made more complex when considering
the localization of a particular bromodomain inside the cell as well.
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Figure 3-7: BDFI-B Dose Response Results. BDF1-B was incubated with degenerate arrays
at varying concentrations (1OnM, 50 nM, 1OOnM).
We further queried the other 13 yeast bromodomains using the BBA.
Surprisingly, despite the similarities between the different bromodomains, we
observed that these bromodomains displayed very different binding preferences.
We compared BDF1 B to the first bromodomain of RSC4 (RSC4-A), a member of
the RSC chromatin-remodeling complex. This bromodomain displayed a
markedly different binding profile, with a distinct preference for a particular subset
of histone peptides (Figure 3-8).
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Figure 3-8: RSC4-A BBA Results. RSC4-A was incubated with the degenerate peptide array at
a concentration of 50 nM. Unbound bromodomain was washed off; bromodomains were
transferred to a nitrocellulose membrane and incubated with an anti-GST antibody and visualized
using LICOR.
Extending the BBA to all yeast bromodomains revealed that a wide array
of preferences exist for the bromodomains across the peptidome. Broadly, these
bromodomains can be categorized as bromodomains that bind generically across
the acetylproteome, bromodomains that have a strong amino acid preference,
histone-binders, and non-binders.
To utilize the bromodomain as an affinity reagent, we developed a low-
throughput profiling technique capable of specifically identifying both proteins and
their sites of acetylation. This technique is similar to classical antibody-based
affinity capture proteomic methods where an antibody raised against a particular
protein modification is incubated with a lysate to enrich for modified peptides.
Here, to directly identify the diverse subsets of proteins/peptides captured by
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bromodomains, we have substituted double-tagged bromodomains for the
antibody. Protein lysates were digested with trypsin and prepared for mass
spectrometry analysis. Peptide samples were pre-cleared with Ni-NTA agarose
for two hours and then incubated with double-tagged bromodomains overnight.
Ni-NTA beads were then added to the bromodomain-peptide mixture for two
hours to capture bound complexes of bromodomain and peptides. Beads were
then washed and peptides were eluted at low pH and analyzed using mass
spectrometry.
Using BDF1-B, we successfully enriched for acetyllysine-containing
peptides. The results, summarized in Figure 3-10, corroborated the trends
observed utilizing alternate techniques to profile the acetylproteome. BDF1-B
enriched for peptides representing a diverse set of proteins. Querying the
proteins bound for their biological roles reveals that bromodomains bind to
proteins with a wide array of biological functions suggesting a potential
expansion for the roles of bromodomains beyond transcriptional regulation to
include metabolic regulation and signal transduction. This diversity in binding is
also represented in their sequence logo (Figure 3-9A). To further enhance this
mass-spectrometry based profiling of the acetylproteome, these approaches
could be coupled to stable isotope labeling (e.g., stable isotope labeling of amino
acids in culture (SILAC) or isobaric tags for relative and absolute quantitation
(iTRAQ)) to quantify lysine acetylation across multiple conditions. In the
bromodomain pullown, we used 4 mg of input material and 12 ug of
bromodomain. In previous large scale screens of the acetylproteome, others
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have utilized tens of milligrams of proteins and tens of micrograms of antibodies.
Results from mass spectrometry-based acetylproteome studies have suggested
that the antibodies perform at a non-specific binding rate of 80 - 90% (Guan et
al., 2010). BDF1B performs near that rate with much less protein than previously
reported (Figure 3-9C). Using more protein may increase the number of
enriched peptides using our bromodomain-based approach. However, the
binding affinity of bromodomains is much weaker than antibodies suggesting
washing may significantly affect the observed number of sites and the amount of
specific or nonspecific binding.
A
C
0 AcK *non-AcK
Figure 3-9: BDFI-B Peptide Pulldown Results. (A) Sequence motif of acetylated peptides
pulled down in the analysis. (B) GO Term analysis of biological processes associated with
proteins identified in analysis. (C) Specific versus non-specific binding of BDF1-B.
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Recognizing the challenges introduced by using a single bromodomain,
we engineered fusion proteins expressing two bromodomains. Many
bromodomain-containing proteins express multiple bromodomains in a single
protein, which may confer a higher affinity for acetylated proteins due to an
avidity effect. To assess the effects of expressing bromodomains in tandem, we
expressed two fusion constructs: a naturally occurring tandem pair occurring in
BDF1 and a hybrid pair containing the GCN5 bromodomain and the second
bromodomain from BDF1 (Figure 3-11).
Single Fusion
GCN5 GCN5Lzj5 LEJ-
Figure 3-10: Single Bromodomains and Engineered Fusion Proteins. Tandem bromodomain
constructs were created by linking the first bromodomain of BDF1 and the second bromodomain
of BDF1. A second construct was created by linking GCN5 with the second bromodomain of
BDF1.
We compared the binding kinetics of the five protein constructs, consisting
of three individual bromodomains and two fusion proteins, to an acetylated
histone peptide (H4K12) using surface plasmon resonance (Table 3-1). The
construct containing the two bromodomains from BDF1 had the highest affinity
for the histone peptide while the construct containing the GCN5 bromodomain
alone had the lowest affinity. Using a bi-layer interferometry instrument also
preliminarily validated these trends. Combining bromodomains in tandem
101
improved the binding affinity of the engineered proteins. The enhancement in
binding affinity differed depending on the two bromodomains combined
suggesting that a library of different constructs may yield a wide array of reagents
with different binding affinities. One outstanding question remaining concerns
how these engineered fusion proteins behave against the degenerate peptide
array.
Table 3-1
Protein Ko (M)
BDF1-A 1.11X10-6
BDFI-B 2.14x10-7
BDFI 1.67x10-
GCN5 2.25x1 0-5
GLB 1.08x1 0-7
As an alternative strategy to improve the binding affinity of the
bromodomains, we employed yeast surface display as a method for directed
evolution of bromodomain affinity (Ackerman et al., 2009). Briefly, we expressed
BDF1-B in a yeast surface display vector, placing it between c-myc and HA tags
(Figure 3-12).
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Figure 3-11: Yeast Surface Display Schematic. Yeast surface display was utilized as a
strategy to improve the affinity of bromodomain. Bromodomains were cloned into a yeast surface
display construct, transformed into yeast cells, and then induced to display on the yeast surface
couched between an HA tag and a c-myc tag.
After transforming this construct into yeast, we first queried the display
and function of the native bromodomain in the yeast surface display vehicle.
Induced cultures of yeast were pelleted, incubated with c-myc and HA antibodies,
and then incubated with fluorescent secondary antibodies. Induced and labeled
cells were then analyzed using flow cytometry (Figure 3-13). The right panel of
Figure 3-13 effectively demonstrates successful display of BDF1-B; 70% of the
cells analyzed appear in the upper right quadrant, which would indicate
fluorescence due to both the HA and c-myc tags.
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Figure 3-12: Yeast Surface Display of BDFI-B. Uninduced transformed EBY100 cells were
used to serve as a flow cytometry gating control (left) and full length display of BDF1 -B was
confirmed by double-incubation with HA and c-myc antibodies.
After confirming display of BDF1 B on the surface of the yeast proteins, we
assayed the function of the bromodomains on the surface of the yeast. Briefly, a
biotinylated degenerate acetyllysine library was allowed to pre-complex with
fluorescent streptavidin reagents. Induced yeast cultures were pelleted,
incubated with c-myc antibodies, washed, and then incubated with pre-
complexed peptide libraries. Yeast cells were analyzed using flow cytometry
(Figure 3-14).
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Figure 3-13: BDF1B binding with pre-complexed a biotinylated degenerate acetyllysine
peptide library. A fluorescent acetyllysine library was incubated with transformed yeast cells.
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After binding, cells were incubated with a c-myc antibody. Cells were visualized using flow
cytometry.
Despite the small amount of binding, we next generated a mutant library of
bromodomains using error-prone PCR. These libraries were screened as above;
however, minimal binding was observed. Furthermore, subsequent experiments
with the native bromodomain did not reveal the pronounced peptide-binding
signal as was observed in earlier experiments. To investigate the lack of binding
in yeast surface display, future experiments will investigate the role of the GST
tag in bromodomain function. Should the lack of the GST tag influence binding, a
new yeast surface display construct will be generated with a GST tag.
Discussion
Despite the emergence of lysine acetylation as a post-translational
modification that lies central to a complex network of readers, writers, and
erasers, much of the literature surrounding bromodomain-protein interactions has
focused on the interaction of bromodomains with histones. The emergence of
lysine acetylation as a proteome-wide modification suggests that bromodomains
may also have roles in the regulation of activities outside the nucleus and
histones. To answer this question and determine the broader binding
specificities of the bromodomains, we queried bromodomain binding preferences
across the peptidome using a degenerate peptide library. We identified
bromodomains with a very promiscuous behavior across the acetylproteome,
such as BDF1-B, bromodomains bound specifically to a subset of histone
peptides such as RSC4-A, and bromodomains that did not appear to bind
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acetyllysine, at least under the conditions of this assay. While these experiments
were performed with yeast bromodomains, it is entirely conceivable that similar
patterns could be observed with the human bromodomains, though there is no
human ortholog of BDF1-B.
The degenerate peptide library experiments demonstrated a wide array of
binding preferences for the yeast bromodomains, a behavior that is similar to that
seen previously for other protein domains, including SH2 domains (Machida,
2007). However, while there exists a reasonable amount of literature
surrounding the biological interactions and functional phenotypic roles of
particular phosphotyrosine binding domains, there remains a great deal of
ambiguity for the bromodomains, which have been largely implicated only in
transcriptional control.
Despite the analogy to other protein domains, bromodomains have not
been explored as a tool for exploring various aspects of acetylation biology.
Here, we have demonstrated that we can use bromodomains as an affinity
reagent for enrichment of proteins and peptides. While these experiments used
yeast bromodomains to capture proteins and peptides derived from human
samples, one could generate the entire library of human bromodomains and
perform identical experiments. The results of these experiments would reveal
potential interactions that may occur in vivo and thereby assist in incorporating
bromodomain-protein interactions into acetylation network topologies.
Fusion bromodomains were utilized in an attempt to modulate the binding
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affinity of the bromodomains in an affinity enrichment experiment. Here, we
generated two fusion bromodomains: BDF1, a naturally occurring bromodomain
and GLB, a fusion combining GCN5 and the second bromodomain of BDF1; both
fusion bromodomains utilized the linker from BDF1. Although two combinations
of bromodomains were tested, there exist almost 200 possible combinations of
engineered protein constructs composed of two yeast bromodomains, each of
which may each have their own acetyllysine binding specificity and kinetics,
therefore allowing for an expansive library of acetyllysine affinity reagents. This
library could further be expanded to incorporate the human bromodomains,
thereby increasing the total to 70 different individual bromodomains, and nearly
5000 combinations if done in a pairwise fashion. Furthermore, the linker utilized
in the protein design could be further engineered. At one limit, a very short
peptide linker may bias toward the enrichment of multiply acetylated peptides
such as many of the histone peptides; although, it remains to be seen whether
two bromodomains could bind to adjacent acetylated lysines. At the other limit, a
long linker may provide more flexibility for a more diverse range of binding.
Lastly, we utilized yeast surface display as an alternative strategy to
affinity enrich the bromodomains. However, the results of these experiments
were inconsistent, and we were unable to observe consistent binding of these
bromodomains with the acetyllysine peptide library. In the BBA and pulldown
experiments, we utilized recombinant bromodomains that were N-terminally GST
tagged and C-terminally 6xHis tagged; however, in the yeast surface display
experiments, the bromodomains were N-terminally HA-tagged and C-terminally
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Myc-tagged. While the size of the Myc and 6xHis tags are not that different in
size, the GST tag is 26 KDa while the HA tag is 1.1 KDa. This size difference
may alter the conformation of the bromodomain in the yeast surface display
format as compared to the BBA format, and may explain the lack of binding
observed in the FACs experiments.
In conclusion, we have presented a framework for the development of
affinity reagents based on bromodomains. We first profiled all yeast
bromodomains and demonstrated that these bromodomains display a wide array
of binding preferences across the acetylproteome. Furthermore, we
demonstrated that these bromodomains may effectively function as affinity
capture reagents and present two methods for the improvement of their binding
affinities.
Materials and Methods
Bromodomain Generation
Bromodomain DNA sequences were prepared by PCR. Primers were
designed to perform PCR to produce the 14 bromodomains occurring in the
yeast genome with a 6XHis C-terminal tag. Furthermore, a last primer set was
designed to produce an empty vector containing no bromodomain but simply the
N-terminal GST tag and the C-terminal 6XHis tag. PCR reactions were
performed using the Phusion High-Fidelity polymerase (New England Biolabs).
Briefly, polymerase was mixed with forward and reverse primers (final
concentration: 0.5 uM), template DNA, dNTPs (final concentration: 200 uM),
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reaction buffer, and nuclease free water to a total concentration of 50 uL. The
template DNA for the PCR reactions was the yeast genome.
PCR reactions were performed as follows:
(1) Hot start at 98C
(2) Initial denaturation: 30 seconds at 98C
(3) Denaturation: 10 seconds at 98C
(4) Annealing: 35 seconds at 65C
(5) Extension: 45 seconds at 72C
(6) Steps 2 through 5 were cycled 35 times
(7) Final Extension: 10 minutes at 72C
(8) Hold at 4C
The primers used for the reactions are summarized in Table 3-1 below.
Table 3-2: Bromodomain Cloning Primers
BDF1_A
b'-CAA ACC CGG TC CU (
ATA TGA ATA ATC TCC
CTC AGA ATC CAA TAC
CAA AGC ACC AGC AG-3'
b ' -TTT UTC U A ATO ATU
ATG ATG ATG ATG ATG
CTT GGC TAT TAC AGG
TGG AGC ATC CTT AGC-3'
5'-CGG GCC CGG GTG AAT 5'-GGA GGG CTC GAG ATG
CGA AGA AAC CGA AAT ATG ATG ATG ATG ATG
BDF1_B CCA AAA GAC TAC AAC ATC TTC ATC GGA ATC
AAG CAA TGA AAT TT-3' GTA GTC ATC CAA-3'
5'-CAA ACC CGG GTG CGT 5'-GGA GGG CTC GAG ATG
TGG AAG CTG AAA TGG ATG ATG ATG ATG ATG
BDF2_A AAG CGG AGG AAC TAC CTT CAA GGC AGA AGC
CAC CAC ACC AAA GT-3' GGG TAA AAC GCG-3'
5'-CGG GCC CGG GTG AAA 5'-GGT GGG CTC GAG ATG
ACT CCA AAC CAA AAT ATG ATG ATG ATG ATG
BDF2_B CAA AGA CTT TAC AAA TGA ATC CGT TTC AAT
AAA AAT TCA GGA CT-3' TTC ATT CAA AAT-3'
5'-CAA ACC CGG GTA TGG 5'-TGG GTG GGT GGG CTC
ATG CGT TGG CAC AAC GAG ATG ATG ATG ATG
GCN5 GTC CCA AGC GTG GTC ATG ATG ATC AAT AAG
CAC ACG ATG CAG CA-3' GTG AGA ATA TTC-3'
5'-CAA ACC CGG GTA TGG 5'-GGG CTC GAG ATG ATG
RSC1_A TGG AGC AAG ATA ATG ATG ATG ATG ATG TGG
GGT TTT TAC AGA AGC ATA TGT CAC CTC GGG
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TAC TCA AAA CAC AA-3' ATA ATG TTT TCT-3'
5'-CAA ACC CGG GTG GTA S'-GGG CTC GAG ATG ATG
RSC1_B GAC CAC CAG TAA TTG ATG ATG ATG ATG TTCATC TAC CCT ATG TAC AGG TAA ATA GTC TTC
TGA GGA TTA AGA AT-3' ATC AGG TTT GGA-3'
5'-CGG ACC CGG GTT CGT 5'-CGG CTC GAG ATG ATG
RSC2_A CCA CTC AAA ACT CAA ATG ATG ATG ATG AGGGCG CAT TAG ACA AGG ATA CAC TAA TTG AGG
ACC TGA GGA AAG AA-3' ATA TTT TTC TTT-3'
5'-CGG ACC CGG GTG GGA 5'-CTG CTC GAG ATG ATG
RSC2_B GAC CCC CAA TCA TCG ATG ATG ATG ATG TTCACT TAC CGT ATA TTC TGG AAT GAA ACT TCT
AAA GAA TGA AAA AT-3' ATC AGG TTT GGA-3'
5'-CGG ACC CGG GTA AAT 5'-CTG CTC GAG ATG ATG
RSC4_A CTG AAC TTT TTC TAG ATG ATG ATG ATG AATATG ACT GGC ATA TAC TAA GTA ATT TCT TTT
CTA AAT TTA ATC GA-3' CAA ATT TTT TGC-3'
5'-CGG ACC CGG GTA ATT 5'-CTG CTC GAG ATG ATG
RSC4_B TGA AAA GAA ATT ACT ATG ATG ATG ATG ACGTAA TTA ACA GCG AGG TTC ATT TAA ATC CTG
TCA AAG CCA AAT TA-3' TAA CTC TGG GAA-3'
5'-CGG ACC CGG GTC CTA 5'-CTG CTC GAG ATG ATG
SNF2 TTG ATA TTA GAG AGA ATG ATG ATG ATG AGTAAG TTG CTA AAC AAG AAA GTC GAG TTG TGA
CTC TAG ACT TAT AC-3' GTT ATC GCC-3'
5'-CGG ACC CGG GTA ATC 5'-CTG CTC GAG ATG ATG
SPT7 GGT CAA AAT GGA CAT ATG ATG ATG ATG ATCCGG ATG AAA GAA TTG AGC CCT GTT TCG GAT
GGC AAG AGG AAT TA-3' TGT GAT ATT GGT-3'
5'-CGG ACC CGG GTT CCA 5'-CTG CTC GAG ATG ATG
STH1 AGT CGC TTG GGA TTT ATG ATG ATG ATG CGATTC CCA CGG TGG AAA AGA GTG TTC CTT GAA
AAT TGG TGG AAG AA-3' CCA TTC ATC AGT-3'
5'-TCG AGA CGC GTT TAA TGG TGA TGG TGA TGG TGAGST-HIS C-3'
PCR products were separated via gel electrophoresis on agarose gels.
Gel purification of bromodomain PCR products was performed using a gel
extraction kit (Qiagen). Purified PCR products were subsequently doubly
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digested with Xma1 and Xhol. Small digest products were separated using a
modified PCR cleanup protocol. The vector, PGEX-4T1, was digested using
identical methods to the PCR product digestion. Digested PGEX-4T1 was
separated by gel electrophoresis on an agarose gel. PCR insert-vector ligations
were performed at a 7:1:1:1 ratio (insert:vector:ligase buffer:ligase) overnight at
4C. Ligation products were transformed into DH5a cells by heat shock.
Transformed cells were plated on LB agar plates containing ampicillin and
incubated at 37C overnight. Colonies were selected; small scale cultures were
produced, and DNA was extracted using a Qiagen Mini-Prep kit. DNA was
submitted for sequencing by GeneWiz. Sequencing primers are shown in Table
3-2.
Table 3-3: Bromodomain Sequencing Primers
Forward 5'-TAT AGC ATG GCC TTT GCA GG -3'
Reverse 5'-GGA GCT GCA TGT GTC AGA GG-3'
Following successful sequencing, bromodomain DNA was transformed
into Rosetta-gami(DE3)pLysS cells. Transformed cells were plated on LB agar
plates containing ampicillin, kanamycin, chloramphenicol, and tetracycline and
allowed to grow overnight at 37C. Colonies were subsequently prepared for
small scale cultures and then large scale (500 mL) cultures. Once the large-
scale cultures reached an OD600 of 0.5, 1M IPTG was added at 1:1000 to a final
concentration of 1 uM. Samples were incubated overnight with shaking at 37C.
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Samples were spun down, supernatants decanted, and resuspended in water
and 1OX PBS. DTT was added to a final concentration of 5 mM, and protease
inhibitor was added at 1:100 (Halt, Thermo Scientific). Cells were lysed using
sonication. Following sonication, samples were spun down and the supernatants
from these samples were mixed with rinsed glutathione-sepharose beads (GE
Healthcare) and allowed to incubate for 2 hours with rotation at 4C. Beads were
next spun down, washed seven times with PBS/1% Triton, and then five times
with PBS alone. GST-tagged proteins were eluted with GST elution buffer (50
mM Tris-HCI, 10 mM glutathione, pH 8.0). Each elution was conducted for 30
minutes with rotation at 4C for a total of four elutions. Pooled eluent was
dialyzed against a TBS bath overnight at 4C. Samples were run on SDS-page
gels to evaluate sample purity, and protein concentrations were determined using
a BCA assay.
Fusion Bromodomain Generation
Fusion bromodomains were designed linking the two bromodomains of
BDF1 together (BDF1) as well as a chimera including the sole bromodomain
from GCN5 and the second bromodomain from BDF1 as well as the linker from
BDF1 (GLB). PCR reactions were conducted as described above. Modified
primers were designed for GLB incorporating a new restriction enzyme site for
ACC65. PCR products and vector were prepared for ligation via enzymatic
digest.
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Table 3-4: Fusion Bromodomain Cloning Primers
Linker-BDF1 B Forward
5'-GGC GAG GGT ACC AAC ATA CAA GCT
TCT TTC GAG AAA CAT ATG CTA AAT ATG
CCT GCT AAG GAT-3'
5'-GGA GGG CTC GAG ATG ATG ATG ATG
BDF1B Reverse ATG ATG ATC TTC ATC GGA ATC GTA GTC
ATC CAA-3'
5'-CAA ACC CGG GTA TGG ATG CGT TGG
GCN5 Forward CAC AAC GTC CCA AGC GTG GTC CAC ACG
ATG CAG CA-3'
5'-GGG TGG CTC GAG GGT ACC ATC AAT
GCN5-Chim Reverse AAG GTG AGA ATA TTC AGG TAT TTC TTT
TAC TTT ATT ATT-3'
Ligation was performed sequentially. First, the modified GCN5 insert was
ligated into the digested PGEX-4T1 vector. The ligated vector was then
transformed into DH5a cells, plated, and subsequently prepared into a small-
scale culture. DNA was extracted using a Qiagen mini-prep kit. Insert and
vector were then digested for insertion of BDF1 B. After ligation, DH5a cells were
again transformed, plated on antibiotic plates, and prepared into a small-scale
culture. Extracted DNA was submitted for sequencing by GeneWiz. Preparation
of recombinant protein was performed identically as described above.
Yeast Surface Display
Yeast surface display was performed in an attempt to engineer a mutant
bromodomain using directed evolution approaches. A modified BDF1-B insert
was produced via PCR for ligation into the PCTCON-2 vector, which is used for
yeast surface display. This modified BDF1-B had no N-terminal GST tag or C-
terminal 6XHis Tag. Primers are shown below.
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Table 3-5: Yeast Surface Display Cloning Primers
BDF1 B-PCTCON2-Forward
5'-CGCG GCT AGC
AAA TCC AAA AGA
AAA TTT-3'
GAA TCG AAG AAA CCG
CTA CAA CAA GCA ATG
5'-CGCG GGA TCC ATC TTC ATC GGA ATC
BDF1B-PCTCON2-Forward GTA GTC ATC CAA ATT AGG CCT ATC CGC
CCA TTT-3'
Again, ligated vectors were transformed into DH5a cells, plated, and
prepared as small-scale cultures for DNA extraction. Following confirmation of
successful sequencing, DNA was transformed into EBY100 cells by
electroporation.
Briefly, 250 uL of EBY100 was mixed with 10 uL DNA prepared as
described above. The mixture was added to a pre-chilled 2 mm electroporation
cuvette (Biorad). A square wave for electroporation was produced on a Bio-Rad
Gene Pulser XCell with the following settings: 500V, 15 ms pulse duration, 1
pulse only, 2 mm cuvette. Cells were then resuspended in YPD and incubated at
30C without shaking. After removing small aliquots to estimate number of
transformants, cells were pelleted and resuspended in SDCAA (pH 4.5) and then
allowed to grow until cultures were saturated.
Surface display of the bromodomain was induced by switching the media
from glucose- to galactose-rich media. Yeast cells were pelleted and then
resuspended in 1 L of galactose-rich media (SGCAA) for 12 - 24 hours at 20C.
Sorting for yeast displaying full-length bromodomain clones was
114
performed by isolating yeast that stain double positive for the N-terminal HA
epitope tag and the C-terminal c-myc epitope tag. Cells were pelleted and then
resuspended in 50 uL PBSA and anti-HA and anti-c-myc antibodies were added
at a 1:100 dilution and allowed to incubate for at least 20 minutes. Cells were
next washed to remove non-specifically bound antibodies, and then incubated
with fluorescent secondary antibodies. In the case of experiments assessing the
bromodomain function, fluorescently tagged acetylated peptides were incubated
instead of a secondary antibody. Cells were allowed to incubate on ice for at
least 15 minutes. They were then washed with PBSA and then sorted.
Mutant bromodomain libraries were generated using error prone PCR.
Briefly, error prone PCR was performed in a 50 uL reaction volume using the
GeneMorph random mutagenesis kit. Varying the amount of DNA template
modulated mutation frequency. PCR products were processed as described
above. Introduction of mutations was confirmed by sequencing. Mutant vectors
were transformed into EBY1 00 cells by electroporation.
Bromodomain Binding Assay
Degenerate peptide arrays were washed with TBS three times, for ten
minutes each wash. The membrane was then blocked with 2% milk 0.1% Tween
in TBS (TBST) for 1 hour at room temperature. GST-tagged bromodomains
were diluted to a final concentration of 100 nM in TBST and then incubated with
the degenerate arrays for 1 hour at room temperature. Three quick washes were
performed with TBST. Bromodomains were then transferred to nitrocellulose for
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one hour at 0.85 mA/cm2. Nitrocellulose was then blocked with 2% milk in TBST
for 1 hour. Anti-GST antibody (Millipore) was then added at 1:1000 and allowed
to incubate for an hour at room temperature. Nitrocellulose blots were washed
three times with TBST, five minutes each. Blots were subsequently incubated
with fluorescent secondary antibodies at 1:15000 (Licor). Blots were then
washed with TBST three times, five minutes each and then visualized using an
Odyssey scanner.
A549 Cell Culture
Human non-small cell lung cancer A549 cells were cultured in RPMI with
10% fetal bovine serum, 2mM glutamine, 100 units/ml penicillin, and 100 mg/ml
streptomycin. Prior to lysis, cells were washed briefly with PBS and then
incubated in their respective serum-free media overnight. Cells were
subsequently lysed in in RIPA buffer (150 mM NaCl, 5 mM EDTA, 1% Triton X-
100, 1% deoxycholate, 50 mM Tris, pH 7.4). Protein concentrations were
quantified using the BCA assay.
Bromodomain Protein Pulldowns
For each protein pulldown, one milligram of cell lysate was mixed with 40
pL NTA bead slurry and allowed to incubate for 2 hours at 4C with rotation.
Beads were spun down, and the supernatant was collected. Pre-cleared cell
lysates were mixed with 12 ug purified bromodomain and allowed to incubate
overnight at 4C with rotation. 20 uL washed NTA beads were spiked in and
allowed to incubate with bromodomain-protein complexes for two hours at 4C
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with rotation. Beads were rinsed with RIPA buffer, four times, five minutes each,
and then beads were boiled in 2X laemmli buffer. Pulldown eluents were
separated on 10% SDS-page gels at 120V for 2 hours. Gels were stained for
protein loading using the Simply Stain reagent (Life Technologies). Gels were
also transferred to nitrocellulose for one hour at 1 OOV. Blots were blocked in 5%
milk in TBS containing 0.1% Tween for 1 hour at room temperature.
Bromodomain Peptide Pulldowns and Mass Spectrometry
2 mg of tryptic digests of A549 cells were resuspended in 400 uL IP buffer
(100 mM Tris, 0.3% NP-40, pH 7.4). Samples were then pre-cleared with 40 uL
NTA bead slurry for two hours at 4C (Qiagen). Beads were spun down, and the
supernatant was mixed with 12 ug of bromodomain and allowed to incubate
overnight at 4C with rotation. 40 uL of washed NTA bead slurry was then
introduced to the sample, incubated for two hours, rinsed, and then eluted with
30% acetic acid for thirty minutes. Eluent was loaded directly onto a 200 uM
inner diameter C18 precolumn (fabricated in-house). The precolumn was rinsed
on an HPLC with 0.2 M acetic acid for at least 30 minutes, prior to MS analysis.
Peptides were separated by reverse phase HPLC (Agilent) over a 150 minute
gradient prior to electrospray into an Orbitrap Elite mass spectrometer (Thermo
Fisher Scientific).
Surface Plasmon Resonance (SPR)
Biotinylated HxKy peptides were immobilized onto a streptavidin sensor
chip (GE healthcare). Briefly, the sensor chip surface was conditioned with three
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consecutive 1-minute injections of 1M NaCl in 50 mM NaOH. Biotinylated ligand
was subsequently immobilized via injection. Tagged bromodomains were
injected at 5 uL/min and allowed to associate with the histone peptide.
Dissociation was measured over five minutes. The sample surface was
regenerated with a one minute 10 mM glycine injection followed by a buffer rinse
of five minutes.
Bromodomain Sequence Alignment
Bromodomain amino acid sequences were aligned using CLUSTALW.
Peptide Pulldown Sequence Alignment
To generate bromodomain motifs, acetylated peptides were aligned using
a custom Python script. 15-mer peptides were generated from the Mascot
search results. The acetylated lysine was fixed as the central residue, and the
peptides were aligned to achieve this constraint. In the event, a 15-mer could not
be generated. The remaining positions were treated as blanks. A sequence
motif was then generated using WebLogo (Crooks et al., 2004).
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Chapter 4 : Identification of Acetyltransferase
Substrates
Introduction
Lysine acetylation occurs in the context of a dynamic balance between the
enzymes that add the protein modification, and the enzymes that remove the
modification. Until recently, lysine acetylation has largely only been considered
in the context of histone proteins; however, a number of studies have since
demonstrated that lysine acetylation occurs across the proteome, and is not
uniquely confined to nuclear proteins. While these catalogs of lysine acetylation
sites have been informative in describing the depth and breadth of the lysine
acetylproteome, these site identifications alone cannot provide mechanistic
insight into how the post-translational modification may integrate broadly in
signaling networks in order to modulate cellular responses. Knowing the
enzymes that add or remove a particular protein modification is also important.
Lysine acetyltransferases catalyze the transfer of acetyl-CoA to lysine
residues. These enzymes are subdivided into two categories based on their
cellular localization, cytoplasmic or nuclear, and these acetyltransferases are
further grouped into one of three families based on conservation of particular
structural motifs. These three families are the GNAT family, MYST family, and
p300/CBP family. Shared across all of these acetyltransferases is an Arg/Gln-X-
X-Gly-X-Gly/Ala sequence that is important for acetyl-CoA binding.
The GNAT family of proteins is characterized as being composed of up to
four different protein domains: an amino terminal domain, a HAT domain, an
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interaction domain, and a bromodomain. The prototypical example from this
family is the acetyltransferase GCN5, for which this family is named (Gcn-5
related N-acetyltransferase). The second family of acetyltransferases is the
MYST family, named for its founding members: MOZ, Ybf2, Sas2, and Tip60.
Members of the MYST family are characterized as containing acetyltransferase
domains, zinc fingers and chromodomains, which may mediate protein-protein or
protein-chromatin interactions. The last family, p300/CBP, contains two highly
related proteins, and it has been suggested that they are functionally
interchangeable in cultured cells. This protein family contains many different
protein domains including zinc finger regions, a bromodomain, a HAT domain,
and two different regions that are suggested to mediate interaction with other
transcription factors (Figure 4-1).
Figure 4-1: p3001CBP Domain Structure. The p300/CBP family of proteins contains a variety of
domains that help mediate its interactions with acetyl-CoA, chromatin, and a variety of other
proteins.
Numerous studies have explored the substrate specificity of
acetyltransferases. This substrate specificity has been compared to the
specificity observed in kinase signaling where specific phosphorylation patterns
may give rise to different responses. In vitro studies have demonstrated that
while some acetyltransferases demonstrate strong substrate specificity, others
such as p300/CBP demonstrate less specificity for acetylating histone substrates.
Furthermore, a number of studies have since demonstrated that these enzymes
are capable of acetylating non-histone substrates, including structural proteins
such as tubulin and p53 (Takemura et al., 1992; Tang et al., 2008).
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Despite the ability to observe the effects of the acetyltransferases, we are
only beginning to understand how the acetyltransferase activity is regulated.
Acetyltransferase activity is modulated by phosphorylation and auto-acetylation
(Barlev et al., 1998; Chakravarti et al., 1999; Ait-Si-Ali et al., 1998).
Acetyltransferases often occur in protein complexes, and some have suggested
that these interactions may confer another layer of complexity in the regulation of
these protein activities.
To better understand the role of acetyltransferases in regulating biological
phenotypes, many approaches have been used. Genetic knockout studies in
mice have demonstrated a critical role for many of these enzymes in
development. Mice lacking GCN5, CBP, and p300 all experience embryonic
lethality (Xu et al., 2000; Yamauchi et al., 2000; Yao et al., 1998). Recent
studies have also identified strategies to pharmacologically interfere with the
activity of these enzymes (Bowers et al., 2010). While these studies clearly
demonstrate a role for these enzymes in regulating biological phenotypes,
genetic knockout studies or inhibitor studies do not identify the protein substrates
whose acetylation status may actually influence these biological outcomes. To
address this knowledge gap, methods to identify protein substrates of a particular
enzyme are of critical importance.
Many approaches have been utilized to explore substrate-enzyme
relationships, some biochemical in nature, others computational. For example,
Basu and colleagues described a computational method, PredMod, for the
prediction of acetylation substrates. PredMod uses experimental reports of
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acetylated and non-acetylated histones as the training dataset for a classifier
algorithm (Basu et al., 2009). After the construction of the classifier, the
algorithm is applied to non-histone proteins; acetylation sites are predicted and
confirmed via mass spectrometry. While this approach is a useful complement to
other labor- and reagent-intensive approaches, the algorithm has an associated
false discovery rate and is not a perfect predictor. In the face of imperfect
predictions, experimental validation of an acetylation site using approaches such
as mutagenesis and mass spectrometry will still be necessary. Other motif-
based algorithms have been proposed to explore trends in large-scale
acetylation datasets (Gnad et al., 2010). However, these algorithms have all
focused exclusively on the acetylation of the substrate without connecting back to
the enzymes responsible for the modification. Approaches that are capable of
exploring the relationship between enzyme and substrate at a systems level will
be necessary to better describe the topology of lysine acetylation networks.
Chemical biological approaches have been used to explore enzyme
substrates. This approach was best popularized by Shokat and colleagues when
they mutated the ATP binding pocket of Src to accommodate a bulky ATP analog
(Shah et al., 1997). Functionalization of the analog with a variety of chemical
handles enabled affinity enrichment and kinase substrate identification from cell
lysates (Carlson et al., 2011). This method has since been extended for a
number of different kinases (Horiuchi et al., 2012; Ultanir et al., 2012).
Multiple different approaches have been proposed to study
acetyltransferase substrates ranging from strategies based in biochemistry to
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computational biology. The classical approach relies on an in vitro enzyme
activity assay demonstrating the ability of an acetyltransferase to acetylate a
particular protein of interest, typically confirmed by the detection of a radioactive
acetyl-CoA analog, namely 3H-acetyl-CoA or 14C-acetyl-CoA. In addition to the
confirmation of enzymatic activity, in vivo interaction between the enzyme and
protein of interest can be confirmed via co-immunoprecipitation experiments.
While rigorous, this approach scales linearly with each enzyme-substrate
interaction to be investigated making a systems-level understanding of
acetyltransferase-substrate interactions a significant undertaking.
Other substrate profiling experiments of acetyltransferases have made
use of acetyl-CoA analogs and chemical modification to identify potential
substrates. For example, Yu and colleagues used an acetyl-CoA analog,
chloroacetyl-CoA (Yu et al., 2006). Despite the reduced affinity for this acetyl-
CoA analog, the authors used a variety of acetyltransferases in conjunction with
these analogs to demonstrate protein modification. The labeled substrates were
subsequently labeled using 0.6 mM TAMRA cystamine, and then visualized by
gel fluorescence.
Yang and colleagues recently described an approach, which relies on bio-
orthogonal proteomics to profile substrates of the acetyltransferase p300. In this
study, the authors use an alkynyl acetyl-CoA analog, 4-pentynoyl-CoA (Yang et
al., 2011). Incorporation of the alkyne into the acetylation site enables click-
chemistry (CuAAC), allowing for addition of a fluorescent azide or biotin-azide tag
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for downstream analysis via in-gel fluorescence analysis or mass spectrometry
(Figure 4-2).
In Gel Analysis
+ p300
+ 4-pentynoy-CoA +fluorescent azide
+biotin azide
Cell Lysate
CuAAC
[peptides or proteins]
Mass
Spectrometry
Figure 4-2: Workflow for Acetyltransferase Substrate Labeling. Proteins are reacted with
p300 and 4-pentynoyl-CoA in an in vitro acetylation reaction. Pentynoylated proteins are then
subjected to click chemistry with incorporation of a biotin- or fluorescent-azide. Proteins are
analyzed via gel electrophoresis or mass spectrometry.
The in-gel fluorescence protocol allows the authors to rapidly screen
against a number of conditions; however, this method does not allow the authors
to identify the pentynoylated proteins or the sites of modification. In their mass
spectrometry-based protocol, they identify proteins that may be p300 substrates,
including some histone substrates. This protocol has the potential to identify a
number of acetyltransferase substrates; however, the protocol as described is
subject to a number of potential criticisms.
The first criticism of their in vitro substrate profiling strategy is that the
incubation of p300 with cell lysate may introduce artifacts resulting from the
assay design. Without cell compartments, p300 may be able to interact with
protein substrates it may otherwise may not be able to interact with in an intact
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cell. This critique was subsequently mitigated by the same group with the
introduction of sodium pentynoate as a metabolic precursor of 4-pentynoyl-CoA
thereby allowing the cells to be cultured with this metabolic precursor and
maintain intact cellular compartments. While this approach is also subject to
critique as the enzyme now has both endogenous acetyl-CoA it can utilize in
addition to the 4-pentynoyl-CoA, this was one of the first demonstrations of a
bioorthogonal substrate labeling protocol that utilized in vivo labeling. Another
critique of this approach is that neither the 4-pentynoyl-CoA nor the sodium
pentynoate have been demonstrated to be uniquely utilized by p300; therefore
the modified proteins may not be bona fide p300 substrates, but could instead be
substrates of other acetyltransferases or other protein-modifying enzymes that
are capable of coordinating the reaction complex. Lastly, the authors identify
non-specific binding of the fluorescent azide reagent with the extracted core
histones as well as the HeLa cell nuclear extracts.
Given the descriptive nature of the assay proposed by the authors and the
lack of orthogonal experiments to confirm their substrate findings, it is difficult to
determine the substrates of p300 from these experiments alone. However, this
assay presents a platform that, if modified to incorporate quantitative elements to
address non-specific binding of the azide reagent and utilization of the 4-
pentynoyl-CoA by non-p300 enzymes, could be successfully used as a high-
throughput platform to identify enzyme substrates. In this chapter, we present
the basic framework necessary to achieve such a platform and describe the next
steps to achieve a quantitative acetyltransferase-profiling assay.
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Results
To begin this analysis, we began with a simple reaction including p300
catalytic domain and bovine serum albumin (BSA). To explore all dimensions of
the acetylation reaction, BSA was reacted with or without 4-pentynoyl-CoA (4-
pCoA) in the presence or the absence of p300 to catalyze the reaction. The
experimental conditions are summarized in Table 4-1.
Table 4-1: Pentynoylation In Vitro Reaction Conditions
Sample 1 2 3 4 5 6 7 8
p300 - - - - + + + +
4-pCoA - - + + -- + +
10 ug of BSA were reacted with 125 ng of p300 and 50 uM 4-pentynoyl-
CoA for 2 hours at 30C. The reaction was stopped using chloroform-methanol
precipitation. Pellets were resuspended in 4% SDS in PBS by brief sonication.
Click chemistry was subsequently performed on the resuspended pellets. A
mastermix of click chemistry reagents were added (CuSO4, TCEP, azido-
rhodamine) to the protein solution, briefly vortexed, and allowed to react at room
temperature for 1 hour. The click chemistry reaction was stopped using
chloroform-methanol precipitation. Pellets were resolubilized by brief sonication
in 4% SDS in PBS, and laemmli sample buffer was added to each sample. The
samples were then run on an SDS-page gel, destained, and then visualized on a
Typhoon imager. After fluorescence visualization, the gels were stained with
Coomassie blue in order to visualize protein loading. ImageJ was utilized to
quantify fluorescence intensity across all eight conditions. The results are shown
in Figure 4-3. These results demonstrate that the azide dye non-specifically
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interacts with the protein in a 4-pentynoyl-CoA-independent manner. These
results were observed on several different occasions with multiple different
protocols for labeling and click chemistry.
A
p300 - + - + - + - +
4-pCoA - - - - + + + +
az-Rho - - + + - - + +
Fluor.
Coomassie
B5
4
3
2
0
Figure 4-3: In Vitro Acetylation of Bovine Serum Albumin. An in vitro acetylation reaction
was performed using p300, 4-pentynoyl-CoA, and BSA. Proteins were precipitated using
chloroform-methanol precipitation. Pellets were subsequently reacted with rhodamine azide
using click chemistry. Proteins were again precipitated, and analyzed on an SDS-page gel. Gels
were analyzed on a Typhoon fluorescent scanner.
Despite the inconclusive results observed with the in vitro reaction
performed with BSA, we hypothesized that BSA may not be the best candidate
protein for a simple in vitro acetylation reaction. Instead, we decided to perform
the in vitro acetylation reaction with dialyzed cell lysate. Briefly, A549 cells were
lysed in RIPA buffer with no EDTA. This lysate was then dialyzed overnight
against 1X TBS. Protein concentrations were then measured using a BCA
assay, and then 10 ug of protein per condition were used to perform the in vitro
acetylation reaction exactly as described above. Performing this experiment with
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dialyzed cell lysate revealed that non-specific binding was greatly reduced with
usage of dialyzed cell lysate. Furthermore, some non-specific binding did
remain, though this may be a result of the chloroform-methanol precipitation.
Lastly, strong fluorescent bands were observed regardless of the addition of
exogenous p300 HAT domain. This suggests that there may be residual activity
of the acetyltransferases in the cell lysate. This demonstrates the need for an
approach to be able to distinguish between background labeling and specific
labeling by the added acetyltransferase.
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Figure 4-4: In Vitro Acetylation of Dialyzed Cell Lysate. An in vitro acetylation reaction was
performed using p300, 4-pentynoy-CoA, and 10 ug dialyzed cell lysate. Proteins were
precipitated using chloroform-methanol precipitation. Pellets were subsequently reacted with
rhodamine azide using click chemistry. Proteins were again precipitated, and analyzed on an
SDS-page gel. Gels were analyzed on a LICOR scanner.
Discussion
Using bioorthogonal proteomics, we were able to modify an in vitro
method for the identification of acetyltransferase substrates in whole cell lysate.
Generally, this method could be utilized to identify the substrates of many
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acetyltransferases and help enhance our knowledge of how acetylation networks
are assembled.
Despite these preliminary steps, this method still needs to be modified to
address a few of the current limitations in the assay. First, we observe non-
specific binding of the dye in simple mixtures, as observed with the p300/BSA
experiment as well as when applying this method to cell lysate. We hypothesize
that background activity of endogenous acetyltransferases may contribute to the
background labeling observed in the cell lysate experiments. To circumvent
these limitations, we will need to leverage small molecule inhibition of
acetyltransferases and quantitative proteomics. This method has been applied
by others for the identification of kinase substrate (Carlson et al., 2011). Here,
the authors used an inhibitor of MEK, U0126 to inhibit kinases upstream of ERK2
rendering ERK2 inactive and then the authors could then quantitatively
distinguish between background labeling and true substrates. A similar approach
could be employed for acetyltransferases (Figure 4-5). Briefly, samples could be
labeled using SILAC, mixed in equal amounts and then subjected to a similar
click chemistry protocol as described above. Instead of a fluorescent azide, a
biotin azide would label the proteins, which would allow for subsequent capture
using streptavidin beads. These proteins would then be digested, and analyzed
via mass spectrometry.
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Figure 4-5: Quantitative p300 Substrate Profiling. Samples are labeled using SILAC. Equal
amounts of protein are mixed and then subjected to an in vitro p300 reaction. Instead of
performing click chemistry with a fluorescent azide, a biotin azide labels the proteins. Biotinylated
proteins are captured using streptavidin beads and then digested with trypsin. Samples are
subsequently analyzed via mass spectrometry.
While we describe this protocol for the discovery of substrates of p300,
this protocol could be used for a wide variety of acetyltransferases though the
precise details of the protocol will need to be evaluated for each
acetyltransferase on a case-by-case basis. Furthermore, in order to make the
quantitative assay amenable to all acetyltransferases, it will be necessary to
identify methods to inhibit these acetyltransferases either by mutation or small
molecule inhibition.
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Control
Lastly, to address one of the major critiques of this protocol, moving this
assay to an in vivo system is of critical importance in order to reduce artifacts
from performing this reaction in vitro. Yang and colleagues described a reagent
based on 4-pentynoyl-CoA, sodium pentynoate, which allows for the culture of
cells with this synthetic 4-pentynoyl-CoA precursor allowing the cell to perform
the acetylation reaction with the cell intact (Yang et al., 2010). This will greatly
influence the results observed because protein complexes and cell
compartments will all remain intact and not introduce artificial protein-protein
interactions.
These approaches build on the framework developed in this chapter. This
chapter has demonstrated that 4-pentynoyl-CoA can be utilized as a tool to
identify acetyltransferase substrates, and despite the observed challenges
presented by non-specific binding, we identify modifications to this method that
can be made in order to create a quantitative assay that can help identify
substrate-enzyme relationships and build a more comprehensive portrait of the
acetyllysine signaling network.
Materials and Methods
In Vitro Acetylation of BSA
The in vitro acetylation reaction was performed by incubating 125 ng p300
HAT domain (Millipore) with 10 ug BSA or with or without 100 uM 4-pentynoyl-
CoA in 50 mM Tris, pH 7.9, 10% glycerol for 2 hours at 30C in a total volume of
15 uL in a 1.5 mL microcentrifuge tube. The acetylation reaction was stopped by
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methanol chloroform precipitation. The reaction mix was brought to a total
volume of 100 uL by addition of 85 uL of water and 400 uL methanol and 100 uL
chloroform. The mixture was vortexed vigorously. 300 uL more of water was
then added and vortexed vigorously. The samples were spun on a benchtop
centrifuge at 13,400 rpm for 15 minutes at room temperature. The upper
aqueous phase was discarded. 1 mL of ice-cold acetone was added, and the
tubes were inverted five times. The tubes were spun for 30 minutes at 13,400
rpm at 4C. The supernatant was carefully discarded without dislodging the
pellet. The pellet was dried for 5 minutes at room temperature, and the pellets
were resolubilized in 15 uL 4% SDS in PBS by briefly pipetting up and down and
then 30 seconds of sonication.
Cell Culture and Cell Lysis
Human non-small cell lung cancer A549 cells were cultured in RPMI with
10% fetal bovine serum, 2mM glutamine, 100 units/ml penicillin, and 100 mg/ml
streptomycin. Prior to lysis, cells were washed briefly with PBS and then
incubated in their respective serum-free media overnight. Cells were lysed in
RIPA buffer on ice. Samples were subsequently spun down on a benchtop
centrifuge at 13400 rpm for 30 minutes at 4C. The supernatant was dialyzed
overnight in a 1X TBS bath. Lysate was removed from the dialysis tubing, and
protein concentration was quantified using a BCA assay.
In Vitro Acetylation of A549 Cell Lysate
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The in vitro acetylation reaction was performed by incubating 125 ng p300
HAT domain (Millipore) with 10 ug dialyzed A549 cell lysate or with or without
100 uM 4-pentynoyl-CoA in 50 mM Tris, pH 7.9, 10% glycerol for 2 hours at 30C
in a total volume of 15 uL in a 1.5 mL microcentrifuge tube. The acetylation
reaction was stopped by methanol chloroform precipitation. The reaction mix
was brought to a total volume of 100 uL by addition of 85 uL of water and 400 uL
methanol and 100 uL chloroform. The mixture was vortexed vigorously. 300 uL
more of water was then added and vortexed vigorously. The samples were spun
on a benchtop centrifuge at 13,400 rpm for 15 minutes at room temperature. The
upper aqueous phase was discarded. 1 mL of ice-cold acetone was added, and
the tubes were inverted five times. The tubes were spun for 30 minutes at
13,400 rpm at 4C. The supernatant was carefully discarded without dislodging
the pellet. The pellet was dried for 5 minutes at room temperature, and the
pellets were resolubilized in 15 uL 4% SDS in PBS by briefly pipetting up and
down and then 30 seconds of sonication.
Click Chemistry
A master mix including 4% SDS in PBS, 10 mM azido-rhodamine, 50 mM
TCEP (prepared fresh), 2 mM TBTA and 50 mM CuSO4 was prepared. 10 uL of
the master mix was added to each sample and vortexed vigorously. The reaction
incubated at room temperature for one hour. The reaction was stopped by
methanol chloroform precipitation as described above. Dried pellets were
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solubilized. 5 uL of 4X laemmli buffer and 1 uL BME was added to each sample.
Samples were vortexed, and boiled for 5 minutes at 95C. Samples were spun
down, and loaded on a 10% Tris-HCI SDS-PAGE gel and run at 120 V. The gel
was destained in destaining solution (50% v/v water, 40% v/v methanol, 10% v/v
acetic acid) for one hour and subsequently soaked in water for an hour and then
scanned on a Typhoon fluorescent scanner (Amersham Biosciences) with a 532
nm excitation, 580 nm filter, and 30 nm bandpass. After scanning, the gel was
rinsed three times, five minutes each with water. The gel was then stained with
Coommasie to visualize protein loading. Quantitation of the fluorescence was
performed using ImageJ.
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Chapter 5 : Missing Data in Mass Spectrometry
Datasets
Introduction
While advances in mass spectrometry technologies have improved our
ability to profile proteomes, challenges still remain to profile post-translational
modifications of low abundance, such as tyrosine phosphorylation. This problem
is exacerbated when performing quantitative analyses with iTRAQ when sample
input amounts are fixed, and increased further when analyzing patient samples
where there is a limited amount of material available for analysis.
For example, a profiling experiment of 20 tumor biopsies would require at
least 3 mass spectrometry analyses using the 8plex form of iTRAQ. Given that
many mass spectrometry analyses are performed in a data-dependent manner
wherein peptides are selected for fragmentation based on their precursor
intensity, slight variations from analysis to analysis may give rise to gaps in a
particular dataset. Minimizing these variations are extremely challenging despite
the availability of monoclonal antibodies that recognize phosphotyrosine.
Immunoprecipitations at the peptide level can be variable depending on the pH of
the sample and the stringency of the wash steps. As a result, as the abundance
of a particular species decreases, the probability of being able to observe it
across multiple biological replicates decreases as well.
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A number of different approaches have been proposed to deal with these
gaps in mass spectrometry analyses. The first, and arguably easiest, is to repeat
the immunoprecipitation from the sample. No immunoprecipitation is likely to
capture all of a particular species from a complex sample, and therefore,
performing the immunoprecipitation a second time can capture a subset of those
proteins or peptides not enriched in the first analysis. Technical replicates from
identical samples can also be performed. A second method relies on running the
mass spectrometer in a targeted fashion using multiple reaction monitoring.
Instead of relying on peptide abundance in the precursor scan, an input list of
desired precursor ions is provided to the instrument. The instrument scans the
precursor window for peptides whose masses correspond to the input list of
peptides, and when the peptide mass is observed, the peptide is subsequently
fragmented and quantification is obtained (Wolf-Yadlin et al., 2007). Successfully
executing a multiple reaction monitoring experiment relies on the operator's
ability to find a set of fragment ion masses that can confirm that the precursor
mass of interest was actually observed. Lastly, a variety of statistical approaches
have been proposed to deal with missing data. For example, imputation involves
replacing missing data with substituted values (Efron, 1994). However, the
challenge with imputation is effectively selecting the appropriate value to replace
the missing data with. Different methods have been suggested, and each
method is subject to critique. Depending on the subsequent analysis to be
performed on a particular dataset, imputation may or may not be necessary.
Imputation is recommended in conditions where the data analysis technique to
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be employed is not content-robust. Alternatively, other methods suggest list-wise
deletion of those measurements where there is missing data. However, this
approach can result in the removal of more than 50% of a particular dataset.
With an increasing interest in efforts to profile across multiple different conditions
(more than can be combined in one experiment), techniques to deal with missing
data must be explored. All of these methods require additional effort by the user
to obtain more data, implement alternative methods or compute values for
missing data points. Implemented well, these methods can greatly improve our
ability to generate hypotheses; however few studies have endeavored to explore
how much missing data can be tolerated when computationally analyzing
quantitative mass spectrometry datasets. It is important to note that
computational analysis does not occur in a vacuum, and furthermore, the goal of
computational analysis applied to biological "omics" data should be guided by the
principle of generating testable hypotheses. Acknowledging this goal, this
treatment of computational analysis is intended to generate a set of hypotheses
that can be curated against prior biological knowledge and a wide array of other
biological tools.
In this chapter, we first explore a fundamental question of how much
missing data is tolerable in a particular model. Next, we discuss methods to
reconstruct data matrices in light of missing data. We conclude with some
preliminary results for a prototypical example of missing data in mass
spectrometry analyses.
Results
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Missing Data Tolerance
Relative phosphotyrosine abundance was profiled in glioblastoma tumor
tissues samples. Briefly, tissue samples were homogenized, digested, and
aliquoted into 800 ug samples. Samples were iTRAQ labeled and then
combined for quantitative mass spectrometry analysis. Phosphotyrosine
immunoprecipitations were performed, and IMAC was utilized as a second stage
of phosphotyrosine enrichment. Peptides were eluted onto a precolumn, and
introduced into an Orbitrap Elite mass spectrometer via electrospray over a 150
minute gradient.
After multiple mass spectrometry analyses and manual validation of the
MS/MS spectra, a final phosphotyrosine dataset was assembled using all
measurements containing an iTRAQ measurement for at least one tumor. The
resulting phosphotyrosine dataset was 833x1 5. However, data was missing for
over 7000 measurements (Figure 5-1, left). Complete quantitation was only
observed for 90 phosphorylation sites (Figure 5-1, right).
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Figure 5-1: Quantitative Phosphotyrosine Measurements Across 15 Tumor Patients.
Quantitative phosphotyrosine measurements were made for 15 tumors across multiple mass
spectrometry analyses. These measurements were all normalized to one tumor used across all
analyses. Data is shown in a log2 transformation. All phosphorylation sites observed are shown
in the left figure. Missing data is shown in white. The right figure shows the data where
measurements were made for all 15 tumors.
For each tumor, growth (rho) and diffusion (D) measurements were made
using serial MRI images (Swanson et al., 2003). For all 15 tumors, D/rho
measurements are available. For 12 of these tumors, individual D and rho
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measurements are available. The goal of this analysis was to identify
phosphorylation sites and proteins whose expression was correlated with the
phenotypic measurements. These correlates could serve as potential
therapeutic targets to interfere with the dysregulated growth and diffusion of
these tumors.
In order to identify phosphorylation sites and proteins correlated with
tumor growth and diffusion, correlation analyses were performed using Matlab.
These results laid the groundwork for an underlying model for subsequent
simulations.
To evaluate the effects of missing data, we used the dataset where all
phosphorylation measurements were observed across all tumors, the 90x1 5
dataset. Each phosphorylation site was correlated to the phenotypic data, and
for each phosphorylation site a correlation coefficient, R, was calculated along
with a p-value associated with testing for the hypothesis of no correlation. R was
calculated using Equation 5-1.
E=1 (Xi - X) (Y ?T- =
1 1X y,-fr-ra,- =)2 / l 1( Y2 (Equation 5-1)
Phosphorylation sites were sorted by their p-value from lowest to highest. We
next simulated the effects of missing data by introducing gaps in the data. We
varied the percent of missing data from 0% to 90% (MP, missing percentage). At
each percentage, we assessed how well the model with missing data could
identify the top 5, 10, 15, 20, 25, and 50% (TP, threshold percentage) of the most
statistically correlated sites from the underlying model. For each threshold
146
percentage and missing percentage combination, the simulation was performed
1000 times. The results are shown in Figure 5-2.
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Figure 5-2: Missing Data Simulation. For each threshold percentage, data was randomly
removed from the original data matrix. At each missing percentage (MP), the frequency with
which the most correlated sites from the original model occurred in model with missing data was
counted.
Each curve represents a different threshold percentage. For example, the
pink curve represents the five percent threshold. The five percent threshold
curve tracks the mean frequency with which the top 5% of the most statistically
significant sites from the underlying model occur in the top 5% in the model with
missing data. As expected, as the threshold percentage increases, the mean
frequency increases as well. These trends align with the thought model to
describe the missing data problem framed here and provide a basic framework
for subsequent analyses of this network.
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We selected a threshold percentage of 25% with a desired accuracy of
-70%, where we defined accuracy as mean frequency divided total number of
simulations. Using our simulation results, we determined that we could tolerate
up to 25% missing data.
To reconstruct a larger data matrix, one approach would be a conservative
approach in order to maximize the total number of proteins or phosphorylation
sites. This would involved a stepped process where the sites lacking data for
one tumor are added to the dataset first, then the sites lacking data for two
tumors, and so on. However, this strategy effectively biases towards data
quantity (number of unique proteins/phosphorylation sites) without necessarily an
improvement in quality. Instead, a random matrix reconstruction method was
implemented.
Here, two matrices were generated: one containing data for every protein
or phosphorylation site where measurements were made for every tumor, and a
second matrix where missing data was present. Rows were selected from the
second matrix at random and then appended to the first until the limit of missing
data was met, in this case 25%. Pairwise correlations were performed between
each protein or phosphorylation site and the corresponding phenotypic
measurements. These proteins were sorted by their p-value and those proteins
occurring in the top 25% based on p-value were identified. Due to the random
selection of rows, we ran this matrix reconstruction 100,000 times and counted
the frequency a particular protein or phosphorylation site occurred in the top
25%. After the simulations were performed, the frequency was normalized to the
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number of times a particular protein was included in the correlation analysis.
Independent models were generated correlating mass spectrometry data to
growth and diffusion values separately, as well as their ratios.
As a test of the method, we visualized the phenotypic data and mass
spectrometry data for the sites identified as the most statistically significantly
correlated sites and the least statistically significantly correlated sites. For ease
of visualization, the sites identified here are those where measurements were
made for tumors (Figure 5-3).
A B
2.5 2.5
12 2
1.5 1.5
I1 1
0.5 0.5
0 10
Figure 5-3: Correlation Analysis of Tumor Protein Expression/Phosphotyrosine Signaling
to DIRho Measurements. (A) Top 20 correlated sites with measurements for all 15 tumors.
First row represents the D/Rho measurements. (B) Bottom 20 correlated sites with
measurements for all 15 tumors. First row represents the D/Rho measurements.
As seen in Figure 6-3, we were able to identify several proteins or sites
well correlated with the growth/diffusion ratio. However, due to the nature of the
correlation analysis and the non-transformed measurements, this method is very
sensitive to outliers. This is best demonstrated in 5-3A where the tumor 6 has a
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high D/rho value. Consequently, many of the proteins and phosphorylation sites
most highly correlated also have high values for tumor 6.
In an attempt to reduce this disposition to correlation with outliers, we
transformed the data by performing a log transformation. Matrix data
reconstruction methods were applied as previously described. Results are
shown in Figure 5-4.
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Figure 5-4: Correlation Analysis of Log Transformed Tumor Protein
Expression/Phosphotyrosine Signaling to D/Rho Measurements. (A) Top 20 correlated sites
with measurements for all 15 tumors. First row represents the D/Rho measurements. (B)
Bottom 20 correlated sites with measurements for all 15 tumors. First row represents the D/Rho
measurements.
Transforming the data did have an effect on the identity of the most
correlated proteins and phosphorylation sites. However, it is still discernable that
certain tumors may contribute more to the correlation analysis than others. For
example, tumor 9 seems to influence the correlation analysis results. However,
there are a number of proteins and phosphorylation sites whose correlation to the
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observed phenotype seems to rely more broadly on the measurements across all
the tumors rather than just one of them.
The objective of this analysis was to identify phosphorylation sites or
proteins well correlated with tumor growth and diffusion, as these physical
characteristics of the tumor are oftentimes associated with patient outcomes. To
assess the utility of correlation analyses in identifying proteins relevant to
survival, we investigated the most highly correlated proteins in Rembrandt, and
evaluated the survival for patients with differential gene expression of proteins we
identified as highly correlated with the growth and diffusion measurements
(Figure 5-5, http://rembrandt.nci.nih.gov). Shown in Figure 5-5 is a comparison
of survival between proteins with upregulated levels of nucleosome assembly
protein1-like 1, NAP1L1, (red) versus intermediate levels (yellow), and the
remainder of the GBM patients (blue) for which no information is available about
NAP1 L1. Expression of this gene has a clear correlation with patient survival as
demonstrated by the Kaplan-Meier plot.
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Figure 5-5: Kaplan Meier Plot for Samples with Differential NAP1 L Expression. Using
Rembrandt, we plotted the survival of GBM patients with differential expression of NAP L1,
Nucleosome assembly protein 1-like 1. The log rank p-value between patients expressing
intermediate levels of the gene versus upregulated levels was 0.015.
Discussion
The method described here explores one method for dealing with missing
data in mass spectrometry datasets. Since the distribution of mass spectrometry
measurements in this analysis was quite large, we were cautious to use methods
like imputation where a value would be calculated for these missing data. Each
tumor and protein or phosphorylation site had quite heterogeneous responses;
so instead, we first employed a method to assess the sensitivity of the
computational modeling to missing data. Here, we demonstrated that depending
on the desired accuracy in hypothesis generation, the amount of tolerable
missing data changes. It is likely that the as the constraint for accuracy
decreases, more false hypotheses may be generated; however, it is up to the
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user to decide how they will further curate these hypotheses to decide how many
false leads they can tolerate. In the case of this analysis, we leveraged
Rembrandt as an additional tool to curate the list of identified proteins even
further before proceeding to more costly analyses.
The next step of the correlation analysis would be to investigate how
abnormalities in one tumor may influence the overall prediction and hypothesis
generation. In Figure 5-3, we demonstrated that one tumor can greatly influence
the correlation analysis results. To address this, we are developing a new
algorithm that systematically assesses the effects of each tumor on the proteins
or phosphorylation sites identified as the most highly correlated. This should
mitigate the effects of one tumor disproportionately contributing to the correlation
analysis.
Materials and Methods
Tumor Growth and Diffusion Analysis
Mathematical models were built to describe the proliferation and diffusion
of tumor cells. Serial magnetic resonance images were taken of the patient's
tumor over the course of treatment. These images were imported, and model
parameters were fit for each tumor.
Tumor Homogenization
Tumorbiopsies were homogenized (Polytron) in ice-cold 8M urea, 1 mM
sodium orthovanadate, 0.1% NP-40, and protease and phosphatase inhibitor
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cocktail tablets (Roche) for mass spectrometric analyses. Samples were
homogenized on ice, with 6 x 10 second pulses (full speed), separated by 10
second intervals to prevent heating of the sample. Once homogenization was
complete, tumor lysates were left to settle on ice for 2 minutes. A 50pl aliquot
was taken for BCA protein quantification and the total homogenate was stored at
-800C.
Sample Preparation and Peptide IP
Protein concentration was quantified using a BCA assay and samples
were reduced (10 mM DTT, 560C for 1 hr) and then alkylated (50mM
iodoacetamide, room temperature in the dark for 1 hr). Urea was then diluted
with 100 mM ammonium acetate buffer pH 8.9, and proteins were digested with
trypsin (sequencing grade, Promega) at an enzyme/substrate ratio of 1:100
overnight at room temperature. Trypsin activity was quenched by adding glacial
acetic acid. Urea was removed from the samples by reverse phase desalting
using C1 8 SepPak cartridges (Waters) and peptides were lyophilized and stored
at -80*C.
800 ug of each sample was reacted with two tubes of 8plex iTRAQ with
each label representing one tumor. Lyophilized samples were dissolved in 30 uL
of 500 mM triethylammonium bicarbonate, pH 8.5, and the iTRAQ reagent was
dissolved in 70 uL isopropanol (8plex). The solution containing peptides and
iTRAQ reagent were vortexed, incubated at room temperature for 2 hours and
concentrated to 40 uL. Samples for a particular time course analysis were then
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combined and concentrated to completion. Peptides were then dissolved in 400
uL IP buffer (100 mM Tris, 100 mM NaCl, and 1% Nonidet P-40, pH 7.4) and the
pH was adjusted to 7.4 prior to immunoprecipitation
For phosphotyrosine immunoprecipitations, 60 ug of Protein G beads were
briefly rinsed with IP buffer and spun down. They were then resuspended in 200
uL of IP buffer and allowed to mix for 8 hours with a cocktail of anti-
phosphotyrosine antibodies at 4C (PT66: Sigma, PY-100: Cell Signaling
Technology, 4G10: Millipore). After 8 hours, the beads were spun down, rinsed
once with 400 uL IP buffer and then mixed with resuspended iTRAQ-labeled
peptides and allowed to mix overnight on a rotor at 4C.
A second stage of enrichment was utilized to isolate phoshphorylated
peptides. Eluents were loaded onto an immobilized affinity metal
chromatography (IMAC) (Zhang et al., 2005). Peptides were eluted onto a
precolumn and were separated by reverse phase HPLC (Agilent) over a 150
minute gradient prior to electrospray into an Orbitrap Elite mass spectrometer
(Thermo Fisher Scientific). To correct for slight variations in protein loading, the
mean iTRAQ ratios for all proteins identified in each analysis was used to
normalize the data.
Protein Expression Analysis
iTRAQ labeled peptides were fractioned into 5 fractions using the ZOOM
isoelectric fractionation (IEF) fractionator (Invitrogen) with a set of 6 ZOOM disks
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(pH 3.0, pH 4.6, pH 5.4, pH 6.2, pH 7.0, and pH 10). The anode buffer (7M urea,
2M thiourea, Novex IEF anode buffer, pH 3.0) and thecathode buffer (7M urea,
2M thiourea, Novex lEF cathode buffer, pH 10.4) were generated per
manufacturer's instructions. MilliQ water was added to each iTRAQlabeled
peptide sample to a final volume of 3.35mL. ZOOM carrier ampholytes were
added to each diluted sample at 1/100 dilution and DTT was added to a final
concentration of 20mM. Fractionation was performed using the following
conditions: 2mA current limit, 2W power limit, with 1 OOV for 20 minutes, 200V for
80 minutes, and 600V for 80 minutes.
Following fractionation, each chamber was rinsed with 500uL water, and
the wash was added to the appropriate fraction. Each fraction was acidified with
formic acid and desalted using Sep-Pak C1 8 Plus Light Cartridges (Waters).
Peptides were eluted using 90% acetronitrile in 0.1% acetic acid, and the
samples were reduced in volume to near dryness in a speed-vac (Thermo
Scientific Savant). Each fraction was resuspended in 200uL 0.1% acetic acid,
diluted 1/100 with 0.1% acetic acid and 20pl (equivalent of 640 ng total protein)
was loaded onto an acidified pre-column. Each fraction was separated by
reverse phase HPLC (Agilent) over a 240 minute gradient prior to
nanoelectrospray into a 5600 triple time of flight (ToF) instrument (AB Sciex).
The instrument was operated in positive ion mode. MS spectra were acquired
from m/z 400 to 1800 with a 250 ms accumulation time and MS/MS spectra were
acquired from m/z 100 to 1800 with a 100 ms accumulation time. The top 50
most intense precursor ions (charge states 2-5)above a threshold of 500 counts
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were selected for fragmentation each cycle and the collision energy was adjusted
for iTRAQ.
Protein Expression Data analysis
Relative quantification and protein identificationwere performed with the
ProteinPilot T M software (version 2.0; AB Sciex) using the Paragon TM algorithm
as the search engine.
MS/MS spectra were searched against human protein sequence database
(NCBInr, released May 2011, downloaded from
ftp://ftp.ncbi.nih.gov/genomes/H sapiens/protein/). The search parameters
allowed for carbamidomethylationof cysteines by iodoacetamide and a standard
extensive list of biological modifications that were programmed in the algorithm.
Identified proteins were grouped by the ProGroup algorithm (AB Sciex) to
minimize redundancy. The peptide and protein selection criteria for relative
quantitation were performed as follows. Only peptides unique for a given protein
were considered for relative quantitation, excluding those common to other
isoforms or proteins of the same family. Proteins were identified on the basis of
having at least 2 peptides with an ion score above 95% confidence. Identified
peptides were further excluded from quantitative analyses if (i) the peaks
corresponding to the iTRAQ labels were not detected, (ii) the same peptide
sequence was shared by more multiple proteins or (iii) the peptide sequence was
discordant. The protein sequence coverage was calculated for proteins by the
percentage of matching amino acids from the identified peptides having
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confidence greater than or equal to 95% divided by the total number of amino
acids in the sequence.
Computational Analysis
All computational analysis was performed using Matlab.
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Chapter 6 : Conclusions & Future Directions
Conclusions
The broad goal of this thesis was to develop a quantitative framework with
which to study lysine acetylation. To meet this goal, we developed a mass-
spectrometry based method to investigate the crosstalk between tyrosine
phosphorylation and lysine acetylation. We demonstrated that lysine acetylation
responds rapidly in response to activation of receptor tyrosine kinases across a
wide variety of ligands and cell lines. Next, we demonstrated that inhibition of
Class 1/11 lysine deacetylases modulated tyrosine phosphorylation, both at the
basal level and in the context of EGF stimulation. To investigate this finding
further, we profiled this response in the context of a variety of kinase and
deacetylase inhibitors. Lastly, we identified potential elements of the lysine
acetylation apparatus that may interact with EGFR.
In chapter 3, we developed a strategy for enrichment of acetylated
peptides using bromodomains. We first characterized the binding preferences of
all yeast bromodomains across the acetylproteome using a degenerate peptide
array. We next utilized these bromodomains as affinity capture reagents to
enrich acetylated peptides from complex mixtures. Finally, we employed two
different strategies to generate higher affinity reagents based on the
bromodomains.
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In chapter 4, we described the basic framework for identify
acetyltransferase substrates in a complex mixture using a protocol that makes
use of an acetyl-CoA analog, 4-pentynoyl-CoA and click chemistry. We
demonstrate that this assay has some associated non-specificity and propose
next steps towards a more quantitative assay.
In chapter 5, we tested the limits of missing data in mass spectrometry
datasets to be used for subsequent generation of biological hypotheses.
Taken together, this thesis presents a suite of tools to quantitatively probe
the acetylproteome. These tools will dramatically improve our ability to
understand how biochemical signaling networks are organized as well as
elucidate how lysine acetylation influences diseases such as cancer and
Huntington's disease, both conditions where acetylation has been implicated to
play a significant role. Of critical need in the field of lysine acetylation are tools to
more comprehensively explore the lysine acetylproteome. Antibodies have been
the standard tool to enrich for acetylated proteins and peptides; however,
polyclonal antibodies and antibodies of variable quality interfere greatly with the
ability to perform comprehensive studies of the acetylproteome. We present the
bromodomains as a novel strategy to affinity enrich for the acetylproteome.
Lastly, to further investigate the topology of these networks, quantitative tools to
explore the enzyme-substrate relationships between acetyltransferase and
acetylated protein are necessary to provide pharmacological targets that when
targeted can modulate biological responses. The computational tools presented
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are acetyllysine-agnostic as they can be useful in a wide variety of mass
spectrometry analyses.
Future Directions
Lysine acetylation has long been recognized for its importance in the
regulation of transcriptional activity. Recent reports have demonstrated that
lysine acetylation occurs across the proteome, including metabolic, signaling,
and structural proteins. This thesis confirms the observation that lysine
acetylation occurs across the entire proteome, and provides the provocative and
intriguing observation that lysine acetylation is a dynamic modification whose
levels can be regulated by the activation of receptor tyrosine kinases.
These results suggest a new paradigm with which to study signaling
networks. Classically, many studies have profiled the phosphoproteome
following stimulation with growth factors and have shown interesting temporal
phosphorylation dynamics within minutes. In our analyses, we demonstrate that
lysine acetylation dynamics occur on a similar timescale and the magnitude of
these changes can be dramatic. Taken together with our deacetylase study, we
demonstrate that phosphotyrosine signaling networks and lysine acetylation
networks are integrated. As we continue to study signaling in response to
perturbation of genetic manipulation, mutations, and drug treatments it will
important to recognize that many post-translational modifications will be affected
as the network responds. This will deepen our understanding for how these
diseases are regulated.
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While the previous mass spectrometry analyses of the acetylproteome
have elegantly demonstrated that lysine acetylation occurs outside of the histone
proteins and outside the nucleus, research on the enzymes and protein domains
that interact with lysine acetylation have largely focused on the nucleus. For
example, the studies that laid the foundation for the bromodomain study in
chapter 3 focused exclusively on the histone binding partners of the
bromodomains (Filippakopoulos et al., 2012; Zhang et al., 2010). By
incorporating our knowledge of proteome-wide acetylation, we designed an
oriented peptide library array representing all potential acetylated peptides and
subsequently identified bromodomains that bound a particular subset of these
peptides, bromodomains that did not bind, and lastly bromodomains that bind
generically across the acetylproteome. Leveraging this observation, we
generated an affinity reagent based on this bromodomain as a tool to
complement pan-acetyllysine antibodies. To improve these tools, we used
protein-engineering approaches to improve the affinity of these reagents.
While identification of lysine acetylation sites and characterization of their
dynamic regulation are important first steps, should these sites be identified as
important in the regulation of biological activities, we may want to target the
proteins that modulate the levels of this modification. In order to achieve this
goal, understanding the substrate-enzyme relationships between the enzymes
that regulate the modification and the modified proteins is critically important. We
successfully performed a bioorthogonal in vitro acetylation reaction on whole cell
lysate, though more work needs to be done to characterize these substrates. As
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suggested by several reviews, lysine acetylation is a post-translational
modification of great importance and may rival tyrosine phosphorylation. Here,
we demonstrate that lysine acetylation and tyrosine phosphorylation integrate to
form a larger, more complex signaling network, and biological responses are
likely regulated by the delicate regulation of a combination of these signaling
events, both phosphotyrosine and acetyllysine.
In light of the work described in this thesis, there are a number of future
directions this research may take in order to better understand how dynamic
lysine acetylation is regulated and how it integrates more broadly into
biochemical signaling networks.
In chapter 2, we demonstrated that lysine acetylation changes rapidly in
response to stimulation with growth factors. The exact mechanism the cell
employs to drive these changes still remains incomplete. The inhibitor screen
presented in that chapter provides some insight into how these responses may
be regulated; however, a more comprehensive and detailed analysis of these
responses is needed. For example, we pre-treated the cells with the lysine
deacetylase inhibitor trichostatin A and then profiled the EGF response in these
cells. We observed that we were able to eliminate dynamics on a subset of
acetylation sites with this pretreatment. This implicates the Class 1/11
deacetylases in regulating this response. However, this class of enzymes
involves a number of different deacetylases, and knowing which specific HDAC is
responsible for this would be incredibly informative. Knocking down particular
deacetylases and profiling acetylation dynamics after knockdown is one route to
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understanding this; however, it is entirely possible that deacetylases may
compensate for each other as has been suggested for HDAC1 and HDAC2. As
an alternative to the knockdown strategy, another approach could include using
specific inhibitors against particular HDACs, but few exist for specific
deacetylases save for a few specific examples such as tubacin, an HDAC6
inhibitor. One approach that may provide insight is to adapt the strategy
employed by the Cravatt lab to use activity based profiling to attempt to try and
profile active deacetylases in a cell lysate (Salisbury and Cravatt, 2007).
Alternatively, one could immunoprecipitate deacetylases from an EGF stimulated
lysate and then compare the activities of these enzymes to enzymes
immunoprecipitated from an unstimulated lysate.
While these experiments identify activated deacetylases, they do not
address the mechanism of activation. The same question could be posited about
the acetyltransferases. The literature suggests that deacetylase activity and
acetyltransferase activity can be regulated by phosphorylation. Knowing which
kinases regulate the activity of the enzymes responsible for regulating acetylation
may provide a direct link between phosphorylation networks and acetylation
networks. Furthermore, the assembly of particular protein complexes may
influence the activity of acetyltransferases and deacetylases. Phosphorylation
may influence the assembly of particular protein complexes. Despite the
analogies to tyrosine phosphorylation, one striking difference is the number of
enzymes that have been implicated to regulate tyrosine phosphorylation relative
to the number of enzymes implicated in regulating lysine acetylation. Strictly
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speaking, Alonso and colleagues identified 107 tyrosine phosphatases and
Robinson and colleagues identified 90 tyrosine kinases (Alonso et al., 2004;
Robinson et al., 2000). If the identified deacetylases and acetyltransferases are
the only ones that exist, how do such a small number of acetyltransferases
acetylate so many proteins and how is specificity conferred? If there are
undiscovered acetyltransferases or deacetylases, what are they? For example,
the first mitochondrial acetyltransferase was only recently identified. Either way,
much work remains to identify the remaining deacetylases and
acetyltransferases, identify the proteins they form complexes with, and lastly,
understand their regulation. Complicating our understanding of this further is
chemical acetylation and the role this may play in cells.
Furthermore, there are many unanswered questions regarding the
substrate specificity of acetyltransferases and deacetylases. For example,
Blander demonstrated that SirT1 demonstrates no substrate specificity in vitro
(Blander et al., 2005). In the absence of substrate selectivity, how is it that
SirT1 exerts a physiological role? Do other deacetylases demonstrate similar
promiscuous behaviors? While this question has been answered for some
deacetylases, it has not been for others (Smith et al., 2011). Smith and
colleagues probed SirT3 specificity to a particular subset of peptides from the
mitochondrial proteome and did observe substrate specificity of SirT3, though a
more comprehensive proteome-wide analysis would be useful as well.
Continuing to build this database of enzyme substrates, both for the
deacetylases and acetyltransferases, will help us assemble a more
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comprehensive understanding of how these networks are organized (Linding et
al., 2008; Obenauer et al., 2003; Yaffe et al., 2001).
While we continue to identify novel acetylation sites and quantify their
dynamics in response to a diverse array of cues, it is immensely important to
understand the functional consequence of a particular acetylation site on protein
function. Currently, our knowledge of the role of lysine acetylation is limited to a
very small number of proteins. Characterizing the role of acetylation sites or any
post-translational modification is challenging as a number of different biochemical
behaviors may be modulated: enzymatic activity, protein-protein interactions, etc.
Many strategies to study the role of acetylation of particular proteins have relied
on the mutation of lysine to arginine; however, lysine is a hub for a diverse milieu
of post-translational modifications (Figure 6-1).
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Figure 6-1: Lysine as a Post-Translational Modification Hub. Lysine can be post-
translationally modified in a number of ways, some of them highlighted above.
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As a result, mutation of a given lysine not only means the loss of acetylation, but
the concomitant loss of many other post-translational modifications. Wagner and
colleagues demonstrated a great degree of overlap between the sites of lysine
ubiquitination and acetylation, suggesting that these lysine mutant experiments
may be challenging to interpret (Wagner et al., 2011). For some proteins, it may
be possible to leverage the strategy described by Neumann and colleagues
where they used an E. coi strain engineered to incorporate acetylated lysine at
particular locations using a novel tRNA (Neumann et al., 2009). This approach
may not be generally applicable to all proteins, especially in an in vitro context.
Biochemistry alone may not be sufficient to reconstruct these lysine
acetylation networks. Computation can and will be immensely useful when trying
to generate hypotheses for how these networks are assembled (Huang and
Fraenkel, 2009). In addition to generating a topology, understanding causal
influences between different proteins in the network will also be important. To
achieve this, Bayesian approaches should also be leveraged. These approaches
benefit greatly from sampling nodes under a number of different conditions, but
will require many additional experiments to profile the acetylproteome under an
array of conditions, including perturbation of different nodes and activating the
signaling network using a variety of exogenous stimuli.
In order to have a robust affinity tool for the identification and analysis of
acetylated proteins and peptides, either a high affinity monoclonal antibody
against the modification or a high affinity bromodomain will need to be generated.
Both approaches would provide a biochemical tool that demonstrates minimal lot-
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to-lot variability and can be produced in large quantities. Here, we presented a
platform for the generation of high affinity bromodomains leveraging two
engineering approaches: engineered fusion proteins and yeast surface display.
We explored two different combinations of bromodomains, one naturally
occurring combination of the two bromodomains from BDF1, and a combination
of the Gcn5 bromodomain and the second bromodomain from BDF1.
Furthermore, we utilized the linker from BDF1. Considering the generation of
fusion affinity reagents as a modular design, there are numerous opportunities to
explore different bromodomain combinations (Figure 6-2).
I Bromodomain #2
Figure 6-2: Modular Engineered Affinity Reagent Design. Engineered affinity reagents based
on the combination of two bromodomains with a peptide linker. All three components can be
exchanged in a combinatorial fashion..
There are 14 yeast bromodomains and 56 human bromodomains. Combining
these reagents in a pairwise fashion allows for the generation of up to 4900
different affinity reagents. Swapping the peptide linker increases the potential
number of reagents even further. Simply selecting from the naturally occurring
peptide linkers in the yeast proteins that contain bromodomains introduces four
more peptide linkers that can be used. Varying the length of the linkers may also
influence their function as affinity reagents.
Yeast surface display was also utilized as a means to improve the affinity
of single bromodomains. Despite countless attempts, yeast surface display did
not provide consistent results; however, directed evolution is still a worthwhile
approach. Here, yeast surface display may not have succeeded due to the lack
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of the N-terminal GST tag in the yeast surface display construct. A simple
experiment could be performed to assess the role of the GST tag in binding
ability of the recombinant bromodomain. A directed evolution approach that does
not make use of yeast surface display could also be employed in order to identify
bromodomain mutants with improved binding affinities. These methods could be
other surface display techniques such as phage display. Alternatively, another
method, though low throughput, would be leveraging in vitro translation systems
(Figure 6-3).
1. Mutagenized
bromodomain
DNA library
2. In VitroTranslation
of Bromodomain
Library 3. Addition of
Biotinylated Library
of Acetylated
Peptides at Low
Concentration 4. Capture of High
Affinity Bromodomain
Mutants using
Streptavidin.
5. Sequence Mutants.
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Figure 6-3: In Vitro Translation of Mutagenized Bromodomains and Selection of High
Affinity Binders. A bromodomain DNA sequence is mutagenized and then translated to protein
in vitro. A library of acetylated peptides carrying biotin tags are added to the sample at low
concentrations, and then bromodomain peptide complexes are captured using streptavidin.
Captured bromodomain complexes are sequenced to identify relevant mutations.
Here, a mutagenized library of bromodomain sequences would be translated in
vitro and then a biotinylated library of acetylated peptides could be introduced at
low concentration. Those bromodomains that bind at low concentration could be
captured from the lysate using streptavidin beads, released, and then
sequenced. While this approach may not have the ability to sample as diverse a
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library in the same amount of time compared to methods that utilize flow
cytometry, this approach would reduce any interference that may arise from
surface display.
Lastly, to address the non-specific utilization of 4-pentynoyl-CoA, efforts to
generate acetyltransferase mutants that can accommodate a modified acetyl-
CoA analog will be necessary. Liu et al crystallized Lys-CoA in complex with
p300; this crystal structure will prove useful in generating a bulky analog as has
been done with protein kinases (Liu et al., 2008; Shah et al., 1997). This rational
approach could be complemented by the generation of candidate analogs and
then creating a mutagenized library of acetyltransferase domains and then
looking for binding of the bulky analog. Alternatively, quantitative mass
spectrometry analyses could be used to try to distinguish between background
labeling and non-specific labeling. To achieve this, specific acetyltransferase
inhibitors will be necessary. Bowers and colleagues describe the development of
C646, a dual p300/CBP inhibitor. While C646 is an example of one of the
acetyltransferases for which there is an inhibitor, there are many other
acetyltransferases with no reported specific inhibitor (Furdas et al., 2012).
Furthermore, some acetyltransferase inhibitors may interfere with the ability to
study acetylation in the context of growth factor signaling. Lee demonstrated that
the acetyltransferase inhibitor, curcumin, induces EGFR degradation (Lee et al.,
2011). These data suggest that a concerted effort to profile acetyltransferases
and their substrates will rely on the development of bioorthogonal tools, small
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molecule inhibitors, and quantitative metrics to understand the effects of any
perturbation.
This thesis has presented one of the first studies of biochemical signaling
integrating network-level information from the acetyllysine and phosphotyrosine
network from the same sample. Furthermore, we presented the intriguing result
that demonstrates interconnectivity between these two post-translational
modifications at the network level. Deconstructing the acetylation network into its
components of "readers", "writers", and "erasers", we also identified a diverse
array of binding preferences for the yeast bromodomains suggesting that
bromodomains may play a role outside of the nucleus. Lastly, we modified a
bioorthogonal proteomics method to investigate the substrates of p300. Taken
together with the computational approaches described, these biochemical assays
and reagents serve for the basis for an acetylation network toolkit. However, with
any set of tools, there are countless improvements and modifications that can be
made in order to better accommodate the nuance and details of a particular
biological system.
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